WO2017038873A1 - 尿素誘導体及びその用途 - Google Patents
尿素誘導体及びその用途 Download PDFInfo
- Publication number
- WO2017038873A1 WO2017038873A1 PCT/JP2016/075500 JP2016075500W WO2017038873A1 WO 2017038873 A1 WO2017038873 A1 WO 2017038873A1 JP 2016075500 W JP2016075500 W JP 2016075500W WO 2017038873 A1 WO2017038873 A1 WO 2017038873A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- trans
- synthesis
- phenyl
- mmol
- Prior art date
Links
- 0 *NC(CC1)CCC1O Chemical compound *NC(CC1)CCC1O 0.000 description 4
- XUIWZLFGKJLZRW-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1Oc1ccc(C(F)(F)F)cc1NC(OCC(Cl)(Cl)Cl)=O)=O Chemical compound CC(C)(C)OC(N(C1)CC1Oc1ccc(C(F)(F)F)cc1NC(OCC(Cl)(Cl)Cl)=O)=O XUIWZLFGKJLZRW-UHFFFAOYSA-N 0.000 description 1
- CCQKDDMYZNSRSV-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1)CCC1/C=[O]/c1nc(Cl)ncc1)=O Chemical compound CC(C)(C)OC(NC(CC1)CCC1/C=[O]/c1nc(Cl)ncc1)=O CCQKDDMYZNSRSV-UHFFFAOYSA-N 0.000 description 1
- GGJRMNRSXAYOAC-KYZUINATSA-N CNc1cc(O[C@H](CC2)CC[C@@H]2N)ncn1 Chemical compound CNc1cc(O[C@H](CC2)CC[C@@H]2N)ncn1 GGJRMNRSXAYOAC-KYZUINATSA-N 0.000 description 1
- APHZDHJVKKCYMR-WKILWMFISA-N COc(c(NC(N[C@H](CC1)CC[C@@H]1OCc1ccncc1)=O)c1)ccc1OC(F)(F)F Chemical compound COc(c(NC(N[C@H](CC1)CC[C@@H]1OCc1ccncc1)=O)c1)ccc1OC(F)(F)F APHZDHJVKKCYMR-WKILWMFISA-N 0.000 description 1
- KXYKBCQSINFQHE-IYARVYRRSA-N COc(c(NC(N[C@H](CC1)CC[C@@H]1Oc1nc(-c2cnccc2)ncc1)=O)c1)c(CO)cc1OC(F)(F)F Chemical compound COc(c(NC(N[C@H](CC1)CC[C@@H]1Oc1nc(-c2cnccc2)ncc1)=O)c1)c(CO)cc1OC(F)(F)F KXYKBCQSINFQHE-IYARVYRRSA-N 0.000 description 1
- YZLBBYUJIYSYMZ-WKILWMFISA-N COc(ccc(OC(F)(F)F)c1)c1NC(N[C@H](CC1)CC[C@@H]1Oc1nc(N2CCOCC2)ccn1)=O Chemical compound COc(ccc(OC(F)(F)F)c1)c1NC(N[C@H](CC1)CC[C@@H]1Oc1nc(N2CCOCC2)ccn1)=O YZLBBYUJIYSYMZ-WKILWMFISA-N 0.000 description 1
- YRDMTZJNCDQMJS-JOCQHMNTSA-N COc(ccc(OC(F)(F)F)c1)c1NC(N[C@H](CC1)CC[C@@H]1Oc1ncncc1)=O Chemical compound COc(ccc(OC(F)(F)F)c1)c1NC(N[C@H](CC1)CC[C@@H]1Oc1ncncc1)=O YRDMTZJNCDQMJS-JOCQHMNTSA-N 0.000 description 1
- PUUGUAISPGLEJE-SHTZXODSSA-N COc1c(CO)cc(C(F)(F)F)cc1NC(N[C@H](CC1)CC[C@@H]1Oc1ncccn1)=O Chemical compound COc1c(CO)cc(C(F)(F)F)cc1NC(N[C@H](CC1)CC[C@@H]1Oc1ncccn1)=O PUUGUAISPGLEJE-SHTZXODSSA-N 0.000 description 1
- ANHFHXVLWSWHMA-UHFFFAOYSA-N COc1c(CO)cc(C(F)(F)F)cc1[N+]([O-])=O Chemical compound COc1c(CO)cc(C(F)(F)F)cc1[N+]([O-])=O ANHFHXVLWSWHMA-UHFFFAOYSA-N 0.000 description 1
- ZDGSBLBOPFUDNO-JOCQHMNTSA-N N[C@H](CC1)CC[C@@H]1Oc1ccnc(N2CCOCC2)c1 Chemical compound N[C@H](CC1)CC[C@@H]1Oc1ccnc(N2CCOCC2)c1 ZDGSBLBOPFUDNO-JOCQHMNTSA-N 0.000 description 1
- QXEHKDKPPCVLDV-JOCQHMNTSA-N N[C@H](CC1)CC[C@@H]1Oc1nc(-c2cnccc2)ncc1 Chemical compound N[C@H](CC1)CC[C@@H]1Oc1nc(-c2cnccc2)ncc1 QXEHKDKPPCVLDV-JOCQHMNTSA-N 0.000 description 1
- XCYHDPGKQQVCEL-UHFFFAOYSA-N Nc1cc(C(F)(F)F)ccc1N(CCN1)CC1=O Chemical compound Nc1cc(C(F)(F)F)ccc1N(CCN1)CC1=O XCYHDPGKQQVCEL-UHFFFAOYSA-N 0.000 description 1
- MLNXEJWKHQHMSA-QAQDUYKDSA-N O=C(N[C@H](CC1)CC[C@@H]1Oc1ccnc(N2CCOCC2)n1)Nc1cc(OC(F)(F)F)ccc1OC1COC1 Chemical compound O=C(N[C@H](CC1)CC[C@@H]1Oc1ccnc(N2CCOCC2)n1)Nc1cc(OC(F)(F)F)ccc1OC1COC1 MLNXEJWKHQHMSA-QAQDUYKDSA-N 0.000 description 1
- UOUGVOLJNOQGRO-UHFFFAOYSA-N OCc(cc1)c(C(F)(F)F)cc1NC(OCC(Cl)(Cl)Cl)=O Chemical compound OCc(cc1)c(C(F)(F)F)cc1NC(OCC(Cl)(Cl)Cl)=O UOUGVOLJNOQGRO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- the present invention relates to a urea derivative and its use.
- Discoidin domain receptor 1 (hereinafter referred to as DDR1) is a receptor tyrosine kinase that is activated by insoluble collagen as a ligand, and a discoidin domain having a collagen binding ability outside the cell is formed inside the receptor tyrosine kinase. Each has a domain (Non-patent Documents 1 and 2).
- Non-patent Documents 3 to 5 Clinically, it has been reported that DDR1 expression is increased in non-small cell lung cancer, glioma and breast cancer, and in non-small cell lung cancer the correlation between increased expression and poor prognosis In addition, a correlation with cell infiltration has been reported (Non-Patent Documents 6 to 9).
- Non-Patent Document 6 It has been reported that knocking down DDR1 by RNA interference suppresses bone metastasis of lung cancer cells (Non-Patent Document 6) and decreases the tumorigenicity of colorectal cancer (Non-Patent Document 10).
- Examples of compounds having inhibitory activity against DDR1 include 3- (2- (pyrazolo [1,5-a] pyrimidin-6-yl) ethynyl) benzamide derivatives (Patent Document 1 and Non-Patent Document 11), 4 -((4-Ethylpiperazinyl) methyl) -3-trifluoromethylbenzamide derivatives (Non-patent Document 12) and 4-piperazinylmethyl-3-trifluoromethylbenzamide derivatives (Patent Documents 2 and 3) Has been reported.
- Patent Document 4 a 2,3-dihydro-1H-inden-2-ylurea derivative
- an object of the present invention is to provide a compound having an inhibitory activity against DDR1.
- DDR1 inhibitory activity an inhibitory activity against DDR1 (hereinafter referred to as DDR1 inhibitory activity)
- R 1 represents a trifluoromethyl group, a trifluoromethoxy group or a pentafluorosulfanyl group
- R 2 independently represents a hydrogen atom or a methyl group which may be substituted with one hydroxyl group or one saturated heterocyclyl group having 4 to 6 ring atoms
- R 3 represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 3 carbon atoms, a saturated heterocyclyl group having 4 to 6 ring atoms which may have an oxo group, or R 5 O—
- R 4 represents a phenyl group, a pyridyl group, a pyridazinyl group or a pyrimidinyl group, which may be substituted with one R 6
- m and n each independently represent 0 or 1
- R 5 represents an alkyl
- R 6 represents a carbamoyl group, a phenyl group, a heteroaryl group having 5 or 6 ring atoms, a saturated heterocyclyl group having 4 to 6 ring atoms, or (R 7 ) R 8 N—
- R 7 and R 8 each independently represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms which may be substituted with a hydroxyl group (provided that m and n are 0, and R 4 Except for a phenyl group or a pyridyl group substituted with a carbamoyl group.
- each R 2 is independently a hydrogen atom or a hydroxymethyl group
- R 3 is a hydrogen atom, morpholinyl group, 2-oxopiperazinyl group or R 5 O—
- R 4 is a pyridyl group or a pyrimidinyl group which may be substituted with one R 6
- R 5 represents an alkyl group having 1 to 3 carbon atoms, 3-oxetanyl group, or a nitrogen atom may be substituted with an acetyl group, a 3-azetidinyl group, 3-pyrrolidinyl or 4-piperidinyl group
- R 6 is preferably a carbamoyl group, a pyridyl group, a morpholinyl group or (R 7 ) R 8 N—.
- R 4 is a group represented by one formula selected from the general formulas (IIa) ⁇ (IIc), More preferably, m and n are 0. [Wherein R 9 represents a carbamoyl group, a pyridyl group, a morpholinyl group or (R 7 ) R 8 N—, and a wavy line represents a point of attachment to the general formula (I). ]
- R 4 is a group represented by the general formula (IId) or (IIe), More preferably, one of m and n is 0 and the other is 1. [Wherein R 10 represents a hydrogen atom or a carbamoyl group, and a wavy line represents a point of attachment to the general formula (I). ]
- the present invention also provides an inhibitor of DDR1 containing the urea derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.
- the urea derivative of the present invention and its pharmacologically acceptable salt have high DDR1 inhibitory activity and can be used as an inhibitor of DDR1.
- the urea derivative of the present invention is characterized by being represented by the following general formula (I).
- R 1 represents a trifluoromethyl group, a trifluoromethoxy group or a pentafluorosulfanyl group
- Each R 2 independently represents a hydrogen atom or a methyl group which may be substituted with one hydroxyl group or one saturated heterocyclyl group having 4 to 6 ring atoms
- R 3 represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 3 carbon atoms, a saturated heterocyclyl group having 4 to 6 ring atoms which may have an oxo group, or R 5 O—
- R 4 represents a phenyl group, a pyridyl group, a pyridazinyl group or a pyrimidinyl group, which may be substituted with one R 6
- m and n each independently represent 0 or 1
- R 5 represents an alkyl group having 1 to 3 carbon
- R 6 represents a carbamoyl group, a phenyl group, a heteroaryl group having 5 or 6 ring atoms, a saturated heterocyclyl group having 4 to 6 ring atoms, or (R 7 ) R 8 N—
- R 7 and R 8 each independently represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms which may be substituted with a hydroxyl group (provided that m and n are 0, and R 4 Except for a phenyl group or a pyridyl group substituted with a carbamoyl group.
- Halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- Alkyl group having 1 to 3 carbon atoms means a methyl group, an ethyl group, a propyl group, or an isopropyl group.
- “Saturated heterocyclyl group having 4 to 6 ring atoms” means one or more atoms selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom, or 1 to 5 carbon atoms.
- a monocyclic saturated heterocyclic group having a 4 to 6 membered ring for example, an azetidinyl group, a pyrrolidinyl group, a piperidinyl group, an oxetanyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, a piperazinyl group, or a morpholinyl group. It is done.
- Examples of the saturated heterocyclyl group having 4 to 6 ring atoms in which the ring atom includes a nitrogen atom include azetidinyl group, pyrrolidinyl group, piperidinyl group, piperazinyl group and morpholinyl group.
- the “saturated heterocyclyl group having 4 to 6 ring atoms which may have an oxo group” means that two hydrogen atoms in the methylene group part of the saturated heterocyclyl group having 4 to 6 ring atoms are oxo Means a group which may be substituted with a group, for example, an azetidinyl group, a pyrrolidinyl group, a piperidinyl group, an oxetanyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, a piperazinyl group, a morpholinyl group, a 2-oxoazetidinyl group, 2-oxopyrrolidinyl group, 2-oxopiperidinyl group, 2-oxooxetanyl group, 2-oxotetrahydrofuranyl group, 2-oxotetrahydropyranyl group, 2-oxopiperazinyl
- heteroaryl group having 5 or 6 ring atoms refers to one or more atoms selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom, or 1 to 5 carbon atoms.
- a thiadiazolyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group or a triazinyl group may be mentioned.
- urea derivative represented by the above general formula (I) may have optical isomers and diastereomers, but not only single isomers but also racemates and diastereomers. Also includes stereomeric mixtures.
- the present invention also includes a prodrug of urea derivative (I) or a pharmacologically acceptable salt thereof.
- the prodrug of urea derivative (I) is a compound that is enzymatically or chemically converted into urea derivative (I) in vivo.
- the active body of the prodrug of the urea derivative (I) is the urea derivative (I), but the prodrug itself of the urea derivative (I) may have activity.
- Examples of the prodrug of the urea derivative (I) include compounds in which the hydroxyl group of the urea derivative (I) is alkylated, phosphorylated or borated. These compounds can be synthesized from the urea derivative (I) according to a known method.
- prodrugs of the urea derivative (I) are disclosed in known literature (“Development of Pharmaceuticals”, Hirokawa Shoten, 1990, Vol. 7, p.163-198 and Progress in Medicine, Vol. 5, 1985, p. 2157 to 2161), and may be changed to urea derivative (I).
- the urea derivative (I) may be labeled with an isotope, and examples of the labeled isotope include 2 H, 3 H, 13 C, 14 C, 15 N, 15 O, 18 O and / or 125 I is mentioned.
- Examples of the “pharmacologically acceptable salt” of the urea derivative (I) include inorganic acid salts such as hydrochloride, sulfate, nitrate, hydrobromide, hydroiodide or phosphate, or Oxalate, malonate, citrate, fumarate, lactate, malate, succinate, tartrate, acetate, trifluoroacetate, maleate, gluconate, benzoate, Ascorbate, glutarate, mandelate, phthalate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, aspartate, glutamate or Organic acid salts such as cinnamate are exemplified, and hydrochloride, sulfate, hydrobromide, maleate, benzoate or methanesulfonate is preferable.
- inorganic acid salts such as hydrochlor
- the urea derivative (I) or a pharmacologically acceptable salt thereof may be an anhydride, or may form a solvate such as a hydrate.
- the solvate is preferably a pharmacologically acceptable solvate.
- the pharmacologically acceptable solvate may be either a hydrate or a non-hydrate, but a hydrate is preferable.
- the solvent constituting the solvate include alcohol solvents such as methanol, ethanol, and n-propanol, N, N-dimethylformamide, dimethyl sulfoxide, and water.
- Formula (IIIa) is preferred as the steric configuration of the urea derivative (I) and the compounds described in Reference Examples.
- the urea derivative (I) can be produced by an appropriate method based on characteristics derived from the basic skeleton and the type of substituent.
- the starting materials and reagents used for the production of these compounds can be generally purchased or can be produced by known methods.
- the urea derivative (I) and intermediates and starting materials used for the production thereof can be isolated and purified by known means.
- Known means for isolation and purification include, for example, solvent extraction, recrystallization or chromatography.
- each isomer can be obtained as a single compound by a known method.
- Known methods include, for example, crystallization, enzyme resolution, or chiral chromatography.
- a protecting group may be introduced into these groups, and the protecting group is deprotected as necessary after the reaction. By doing so, the target compound can be obtained.
- hydroxyl-protecting group examples include a trityl group, an aralkyl group having 7 to 10 carbon atoms (eg, benzyl group), or a substituted silyl group (eg, trimethylsilyl group, triethylsilyl group, or tert-butyldimethylsilyl group). .
- amino-protecting group examples include an alkylcarbonyl group having 2 to 6 carbon atoms (for example, acetyl group), a benzoyl group, an alkyloxycarbonyl group having 2 to 8 carbon atoms (for example, tert-butoxycarbonyl group or benzyloxy group) Carbonyl group), an aralkyl group having 7 to 10 carbon atoms (for example, benzyl group) or a phthaloyl group.
- alkylcarbonyl group having 2 to 6 carbon atoms for example, acetyl group
- benzoyl group an alkyloxycarbonyl group having 2 to 8 carbon atoms (for example, tert-butoxycarbonyl group or benzyloxy group) Carbonyl group)
- an aralkyl group having 7 to 10 carbon atoms for example, benzyl group
- a phthaloyl group examples include an alkylcarbonyl group having 2 to 6 carbon atoms (for example
- Examples of the protecting group for the carboxyl group include an alkyl group having 1 to 6 carbon atoms (for example, a methyl group, an ethyl group, or a tert-butyl group) or an aralkyl group having 7 to 10 carbon atoms (for example, a benzyl group).
- the deprotection of the protecting group varies depending on the kind of the protecting group, but is performed according to a known method (for example, Greene, TW, “Green's Protective Groups in Organic Synthesis”, Wiley-Interscience) or a method equivalent thereto. be able to.
- the urea derivative (I) can be obtained, for example, by a ureaation reaction of an aniline derivative (IV) and a cyclohexaneamine derivative (V) in the presence of a urea agent and a base. [Wherein each symbol has the same definition as above. ]
- the aniline derivative (IV) used for the urea formation reaction can be produced by a known method or a method analogous thereto.
- the cyclohexaneamine derivative (V) used for the urea formation reaction can be purchased as a single isomer or a mixture of isomers as necessary. Moreover, it can also manufacture by a well-known method or a method according to it.
- the amount of cyclohexaneamine derivative (V) used for the urea reaction is preferably 0.5 to 10 equivalents, more preferably 1 to 3 equivalents, relative to the aniline derivative (IV).
- Examples of the urea agent used in the urea reaction include, for example, chloroformate derivatives such as 2,2,2-trichloroethyl chloroformate, phenyl chloroformate or p-nitrophenyl chloroformate, triphosgene, phosgene, N, N′— Examples include carbonyldiimidazole or N, N′-disuccinimidyl carbonate, and chloroformate derivatives such as 2,2,2-trichloroethyl chloroformate, phenyl chloroformate or p-nitrophenyl chloroformate, or triphosgene. preferable.
- the amount of the urea agent used in the urea reaction is preferably from 0.1 to 100 equivalents, more preferably from 0.3 to 30 equivalents, based on the aniline derivative (IV).
- Examples of the base used in the urea reaction include organic bases such as triethylamine or diisopropylethylamine, inorganic bases such as sodium hydrogen carbonate or potassium carbonate, metal hydride compounds such as sodium hydride, potassium hydride or calcium hydride, methyl Examples thereof include alkyllithium such as lithium or butyllithium, lithium amide such as lithium hexamethyldisilazide or lithium diisopropylamide, or a mixture thereof, and an organic base such as triethylamine or diisopropylethylamine is preferable.
- organic bases such as triethylamine or diisopropylethylamine
- inorganic bases such as sodium hydrogen carbonate or potassium carbonate
- metal hydride compounds such as sodium hydride, potassium hydride or calcium hydride
- alkyllithium such as lithium or butyllithium
- lithium amide such as lithium hexamethyldisilazide or lithium diisoprop
- the amount of the base used for the urea formation reaction is preferably 1 to 100 equivalents, more preferably 2 to 30 equivalents, relative to the aniline derivative (IV).
- the reaction solvent used for the urea reaction is appropriately selected according to the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- N, N-dimethylformamide, N, N-dimethyl Aprotic polar solvents such as acetamide or dimethyl sulfoxide, ether solvents such as diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-dioxane, ester solvents such as ethyl acetate or propyl acetate, dichloromethane, chloroform or 1,2-
- chlorinated solvents such as dichloroethane, nitrile solvents such as acetonitrile or propionitrile, or mixed solvents thereof.
- Chlorine solvents such as dichloromethane, chloroform or 1,2-dichloroethane, acetonitrile or propylene. Nitriles nitrile are preferred.
- the reaction temperature of the urea reaction is preferably ⁇ 40 ° C. to 200 ° C., more preferably ⁇ 20 ° C. to 150 ° C.
- the reaction time of the urea reaction is appropriately selected according to the reaction temperature and other conditions, but is preferably 30 minutes to 30 hours.
- the concentration of the aniline derivative (IV) used for the urea formation reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
- the aniline derivative (IV) can be obtained, for example, by a reduction reaction of the nitrobenzene derivative (VI) as shown in Scheme 2. [Wherein each symbol has the same definition as above. ]
- the reduction reaction for example, catalytic hydrogenation reaction in the presence of a metal catalyst such as palladium, nickel or platinum in a hydrogen atmosphere, hydrogenation of lithium aluminum hydride, borohydride dimethyl sulfide complex or borohydride tetrahydrofuran complex, etc.
- a metal catalyst such as palladium, nickel or platinum in a hydrogen atmosphere
- hydrogenation of lithium aluminum hydride, borohydride dimethyl sulfide complex or borohydride tetrahydrofuran complex etc.
- metal catalysts such as zinc, iron or tin in the presence of acid
- metal catalysts such as palladium, nickel or platinum under hydrogen atmosphere.
- a one-electron reduction reaction with a metal catalyst such as zinc, iron or tin is preferred in the presence of the reaction or acid.
- Examples of the metal catalyst used in the catalytic hydrogenation reaction include palladium, nickel, platinum, or a carbon support thereof.
- the amount of the metal catalyst used for the catalytic hydrogenation reaction is preferably 0.001 to 5 equivalents, more preferably 0.01 to 1 equivalents, relative to the nitrobenzene derivative (VI).
- the reaction solvent used in the catalytic hydrogenation reaction is appropriately selected depending on the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- alcohol solvents such as methanol or ethanol, acetonitrile or Nitrile solvents such as propionitrile, aprotic polar solvents such as N, N-dimethylformamide or N, N-dimethylacetamide, ether solvents such as diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-dioxane, acetic acid
- An ester solvent such as ethyl or propyl acetate, a chlorine solvent such as dichloromethane, chloroform or 1,2-dichloroethane, or a mixed solvent thereof may be mentioned, and an alcohol solvent such as methanol or ethanol is preferable.
- the pressure of the hydrogen gas used for the catalytic hydrogenation reaction is preferably 1 to 10 atm, and more preferably 1 to 3 atm.
- the reaction temperature of the catalytic hydrogenation reaction is preferably 0 to 200 ° C, more preferably 0 to 100 ° C.
- the reaction time of the catalytic hydrogenation reaction is appropriately selected according to the reaction temperature and other conditions, but is preferably 1 to 72 hours.
- metal hydride reagent used in the hydride reduction reaction examples include lithium aluminum hydride, borohydride dimethyl sulfide complex, and borohydride tetrahydrofuran complex.
- the amount of the metal hydride reagent used in the hydride reduction reaction is preferably 0.1 to 20 equivalents, more preferably 0.1 to 10 equivalents, relative to the nitrobenzene derivative (VI).
- the reaction solvent used in the hydride reduction reaction is appropriately selected depending on the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- aromatic hydrocarbons such as benzene, toluene or xylene
- the solvent include ether solvents such as diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-dioxane, or mixed solvents thereof.
- Ether solvents such as diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-dioxane are preferable. .
- the reaction temperature of the hydride reduction reaction is preferably ⁇ 78 ° C. to 150 ° C., more preferably ⁇ 20 ° C. to 100 ° C.
- the reaction time of the hydride reduction reaction is appropriately selected according to conditions such as the reaction temperature, but is preferably 1 to 72 hours.
- the concentration of the nitrobenzene derivative (VI) used for the hydride reduction reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
- Examples of the acid used for the one-electron reduction reaction include acetic acid, hydrochloric acid, and ammonium chloride.
- the amount of acid used for the one-electron reduction reaction is preferably 0.1 to 20 equivalents, more preferably 0.1 to 10 equivalents, relative to the nitrobenzene derivative (VI).
- Examples of the metal catalyst used in the one-electron reduction reaction include zinc, iron, tin, and halides thereof.
- the amount of the metal catalyst used for the one-electron reduction reaction is preferably 0.1 to 100 equivalents, more preferably 1 to 50 equivalents, relative to the nitrobenzene derivative (VI).
- the reaction solvent used in the one-electron reduction reaction is appropriately selected depending on the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- an acidic solvent such as hydrochloric acid or acetic acid, methanol or ethanol Alcohol solvents such as acetonitrile, nitrile solvents such as acetonitrile or propionitrile, aprotic polar solvents such as N, N-dimethylformamide or N, N-dimethylacetamide, diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-
- An ether solvent such as dioxane, an ester solvent such as ethyl acetate or propyl acetate, a chlorine solvent such as dichloromethane, chloroform or 1,2-dichloroethane, or a mixed solvent thereof includes an acidic solvent such as hydrochloric acid or acetic acid, or Methanol young Ku alcohol solvent such as ethanol are
- the reaction temperature for the one-electron reduction reaction is preferably 0 to 200 ° C, more preferably 0 to 100 ° C.
- the reaction time for the one-electron reduction reaction is appropriately selected according to the reaction temperature and other conditions, but is preferably 1 to 72 hours.
- the concentration of the nitrobenzene derivative (VI) used for the reduction reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
- nitrobenzene derivative (VI) can be obtained, for example, by a nucleophilic substitution reaction between a nucleophile and a nitrobenzene derivative (VIA) in the presence or absence of a base, as shown in Scheme 3. [Wherein each symbol has the same definition as above. ]
- the nucleophile used for the nucleophilic substitution reaction can be purchased. Moreover, it can also manufacture by a well-known method.
- the amount of the nucleophile used for the nucleophilic substitution reaction is preferably 0.2 to 10 equivalents, more preferably 0.5 to 3 equivalents, relative to the nitrobenzene derivative (VIA).
- a base may be used if desired.
- the base to be used include inorganic bases such as sodium hydride, sodium hydrogen carbonate and potassium carbonate, organic bases such as triethylamine, diisopropylethylamine and pyridine, and mixtures thereof.
- the amount of base used for the nucleophilic substitution reaction is preferably 0.5 to 20 equivalents, more preferably 1 to 3 equivalents, relative to the nitrobenzene derivative (VIA).
- the reaction solvent used for the nucleophilic substitution reaction is appropriately selected depending on the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- an alcohol solvent such as methanol or ethanol, acetonitrile or Nitrile solvents such as propionitrile, aprotic polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide or dimethyl sulfoxide, ether systems such as diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-dioxane Solvent, ester solvent such as ethyl acetate or propyl acetate, chlorine solvent such as dichloromethane, chloroform or 1,2-dichloroethane, or a mixed solvent thereof, alcohol solvent such as methanol or ethanol, N, - dimethylformamide, N, N- dimethylacetamide or dimethylsulfoxide aprotic polar solvent or diethyl
- the reaction temperature of the nucleophilic substitution reaction is preferably ⁇ 20 ° C. to 200 ° C., more preferably 0 to 150 ° C.
- the reaction time of the nucleophilic substitution reaction is appropriately selected according to conditions such as the reaction temperature, but is preferably 1 to 60 hours.
- the concentration of the nitrobenzene derivative (VIA) used for the nucleophilic substitution reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
- the cyclohexaneamine derivative (V) can be obtained, for example, by a deprotection reaction of the cyclohexane derivative (VII) as shown in Scheme 4. [Wherein, PG represents a protecting group, and other symbols are as defined above. ]
- the deprotection of the protecting group varies depending on the kind of the protecting group, but is performed according to a known method (for example, Greene, TW, “Green's Protective Groups in Organic Synthesis”, Wiley-Interscience) or a method equivalent thereto. be able to.
- the cyclohexane derivative (VIIA) in which m and n are 0 is, for example, a halogenated heteroaryl derivative (IX) and an alcohol derivative in the presence or absence of a base, as shown in Scheme 5. It can be obtained by a nucleophilic substitution reaction with (VIIIA). [Wherein, X represents a halogen atom, and other symbols are as defined above. ]
- the alcohol derivative (VIIIA) used in the nucleophilic substitution reaction can be purchased as a single isomer or a mixture of isomers as necessary. Moreover, it can also manufacture by a well-known method or a method according to it.
- the halogenated heteroaryl derivative (IX) used in the nucleophilic substitution reaction can be purchased. Moreover, it can also manufacture by a well-known method.
- the amount of the halogenated heteroaryl derivative (IX) used for the nucleophilic substitution reaction is preferably 0.2 to 10 equivalents, more preferably 0.5 to 3 equivalents, relative to the alcohol derivative (VIIIA).
- a base may be used if desired.
- the base to be used include inorganic bases such as sodium hydride, sodium hydrogen carbonate and potassium carbonate, organic bases such as triethylamine, diisopropylethylamine and pyridine, and mixtures thereof.
- the amount of the base used in the nucleophilic substitution reaction is preferably 0.5 to 20 equivalents, more preferably 1 to 3 equivalents, relative to the alcohol derivative (VIIIA).
- the reaction solvent used for the nucleophilic substitution reaction is appropriately selected depending on the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- an alcohol solvent such as methanol or ethanol, acetonitrile or Nitrile solvents such as propionitrile, aprotic polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide or dimethyl sulfoxide, ether systems such as diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-dioxane Solvent, ester solvent such as ethyl acetate or propyl acetate, chlorine solvent such as dichloromethane, chloroform or 1,2-dichloroethane, or a mixed solvent thereof, alcohol solvent such as methanol or ethanol, N, - dimethylformamide, N, N- dimethylacetamide or dimethylsulfoxide aprotic polar solvent or diethyl
- the reaction temperature of the nucleophilic substitution reaction is preferably ⁇ 20 ° C. to 200 ° C., more preferably 0 to 150 ° C.
- the reaction time of the nucleophilic substitution reaction is appropriately selected according to the reaction temperature and other conditions, but is preferably 1 to 30 hours.
- the concentration of the alcohol derivative (VIIIA) used for the nucleophilic substitution reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
- the cyclohexane derivative (VIIB) in which m is 1 and n is 0 includes, for example, an alcohol derivative (X) and an alcohol in the presence of an azo compound and an organic phosphorus compound, as shown in Scheme 6. It can be obtained by Mitsunobu reaction with derivative (VIIIB) or nucleophilic substitution reaction between halogenated heteroaryl derivative (IX) and alcohol derivative (VIIIB) in the presence or absence of a base. [Wherein each symbol has the same definition as above. ]
- the alcohol derivative (VIIIB) used for the Mitsunobu reaction or the nucleophilic substitution reaction can be purchased as a single isomer or a mixture of isomers as necessary. Moreover, it can also manufacture by a well-known method or a method according to it.
- Examples of the Mitsunobu reaction include a method using an azo compound such as diethyl azodicarboxylate or diisopropyl azodicarboxylate and an organic phosphorus compound such as triphenylphosphine or tributylphosphine (reference: Chem. Rev. 2009, No. 1). 109, p.2551-2651).
- the alcohol derivative (X), azo compound and organophosphorus compound used for the Mitsunobu reaction can be purchased. Moreover, it can also manufacture by a well-known method.
- the amount of the alcohol derivative (X) used in the Mitsunobu reaction is preferably 0.5 to 20 equivalents and more preferably 1 to 5 equivalents with respect to the alcohol derivative (VIIIB).
- Examples of the azo compound used in the Mitsunobu reaction include diethyl azodicarboxylate, diisopropyl azodicarboxylate, azodicarboxylic acid bis (2,2,2-trichloroethyl), N, N, N ′, N′-tetramethylazodi. Carboxamide, azodicarboxylic acid bis (2-methoxyethyl) or azodicarboxylic acid di-tert-butyl.
- the amount of the azo compound used in the Mitsunobu reaction is preferably 0.5 to 20 equivalents and more preferably 1 to 5 equivalents with respect to the alcohol derivative (VIIIB).
- Examples of the organic phosphorus compound used for the Mitsunobu reaction include triphenylphosphine, tributylphosphine, and tricyclohexylphosphine.
- the amount of the organic phosphorus compound used for the Mitsunobu reaction is preferably 1 to 20 equivalents, more preferably 0.5 to 5 equivalents, relative to the alcohol derivative (VIIIB).
- the reaction solvent used in the Mitsunobu reaction is appropriately selected depending on the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- an aromatic hydrocarbon solvent such as benzene, toluene or xylene Nitrile solvents such as acetonitrile or propionitrile, aprotic polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide or dimethyl sulfoxide, diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-dioxane Ether solvents, ester solvents such as ethyl acetate or propyl acetate, chlorine solvents such as dichloromethane, chloroform or 1,2-dichloroethane, or mixed solvents thereof, but aromatic carbonization such as benzene, toluene or xylene.
- Ether solvents such Motokei solvent or diethyl ether or
- the reaction temperature of the Mitsunobu reaction is preferably ⁇ 20 ° C. to 200 ° C., more preferably 0 to 100 ° C.
- the reaction time of the Mitsunobu reaction is appropriately selected according to the reaction temperature and other conditions, but is preferably 1 to 30 hours.
- the concentration of the alcohol derivative (VIIIB) used for the Mitsunobu reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
- the amount of the halogenated heteroaryl derivative (IX) used in the nucleophilic substitution reaction is preferably 0.2 to 10 equivalents, more preferably 0.5 to 3 equivalents, relative to the alcohol derivative (VIIIB).
- a base may be used if desired.
- the base to be used include inorganic bases such as sodium hydride, sodium hydrogen carbonate and potassium carbonate, organic bases such as triethylamine, diisopropylethylamine and pyridine, and mixtures thereof.
- the amount of the base used for the nucleophilic substitution reaction is preferably 0.5 to 20 equivalents, more preferably 1 to 3 equivalents, relative to the alcohol derivative (VIIIB).
- the reaction solvent used for the nucleophilic substitution reaction is appropriately selected depending on the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- an alcohol solvent such as methanol or ethanol, acetonitrile or Nitrile solvents such as propionitrile, aprotic polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide or dimethyl sulfoxide, ether systems such as diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-dioxane Solvent, ester solvent such as ethyl acetate or propyl acetate, chlorine solvent such as dichloromethane, chloroform or 1,2-dichloroethane, or a mixed solvent thereof, alcohol solvent such as methanol or ethanol, N, - dimethylformamide, N, N- dimethylacetamide or dimethylsulfoxide aprotic polar solvent or diethyl
- the reaction temperature of the nucleophilic substitution reaction is preferably ⁇ 20 ° C. to 200 ° C., more preferably 0 to 150 ° C.
- the reaction time of the nucleophilic substitution reaction is appropriately selected according to the reaction temperature and other conditions, but is preferably 1 to 30 hours.
- the concentration of the alcohol derivative (VIIIB) used for the nucleophilic substitution reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
- cyclohexane derivatives (VII), cyclohexane (VIIC) in which n is 1 is, for example, as shown in Scheme 7, in the presence or absence of a base, an alkyl halide derivative (XI) and an alcohol derivative (VIIIA). Alternatively, it can be obtained by a nucleophilic substitution reaction with (VIIIB). [Wherein each symbol has the same definition as above. ]
- the above alcohol derivatives (VIIIA) and (VIIIB) can be purchased as a single isomer or a mixture of isomers as necessary. Moreover, it can also manufacture by a well-known method or a method according to it.
- the halogenated alkyl derivative (XI) used for the nucleophilic substitution reaction can be purchased. Moreover, it can also manufacture by a well-known method.
- the amount of the halogenated alkyl derivative (XI) used for the nucleophilic substitution reaction is preferably 0.2 to 10 equivalents, more preferably 0.5 to 3 equivalents, relative to the alcohol derivative (VIIIA) or (VIIIB).
- a base may be used if desired.
- the base to be used include inorganic bases such as sodium hydride, sodium hydrogen carbonate and potassium carbonate, organic bases such as triethylamine, diisopropylethylamine and pyridine, and mixtures thereof.
- the amount of the base used for the nucleophilic substitution reaction is preferably 0.5 to 20 equivalents, more preferably 1 to 3 equivalents with respect to the alcohol derivative (VIIIA) or (VIIIB).
- the reaction solvent used for the nucleophilic substitution reaction is appropriately selected depending on the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- an alcohol solvent such as methanol or ethanol, acetonitrile or Nitrile solvents such as propionitrile, aprotic polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide or dimethyl sulfoxide, ether systems such as diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-dioxane Solvent, ester solvent such as ethyl acetate or propyl acetate, chlorine solvent such as dichloromethane, chloroform or 1,2-dichloroethane, or a mixed solvent thereof, alcohol solvent such as methanol or ethanol, N, - dimethylformamide, N, N- dimethylacetamide or dimethylsulfoxide aprotic polar solvent or diethyl
- the reaction temperature of the nucleophilic substitution reaction is preferably ⁇ 20 ° C. to 200 ° C., more preferably 0 to 150 ° C.
- the reaction time of the nucleophilic substitution reaction is appropriately selected according to the reaction temperature and other conditions, but is preferably 1 to 30 hours.
- the concentration of the alcohol derivative (VIIIA) or (VIIIB) used for the nucleophilic substitution reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
- the cyclohexane derivative (VIIA-b) in which R 4 is a halogenated heteroaryl is, for example, a dihalogenated heteroaryl derivative (in the presence or absence of a base, as shown in Scheme 8).
- XII) and an alcohol derivative (VIIIA) are as defined above.
- R 11 represents a phenyl group, a pyridyl group, a pyridazinyl group or a pyrimidinyl group, and other symbols are as defined above].
- the alcohol derivative (VIIIA) used in the nucleophilic substitution reaction can be purchased as a single isomer or a mixture of isomers as necessary. Moreover, it can also manufacture by a well-known method or a method according to it.
- the dihalogenated heteroaryl derivative (XII) used for the nucleophilic substitution reaction can be purchased. Moreover, it can also manufacture by a well-known method.
- the amount of the dihalogenated heteroaryl derivative (XII) used in the nucleophilic substitution reaction is preferably 0.2 to 10 equivalents, more preferably 0.5 to 3 equivalents, relative to the alcohol derivative (VIIIA).
- a base may be used if desired.
- the base to be used include inorganic bases such as sodium hydride, sodium hydrogen carbonate and potassium carbonate, organic bases such as triethylamine, diisopropylethylamine and pyridine, and mixtures thereof.
- the amount of the base used in the nucleophilic substitution reaction is preferably 0.5 to 20 equivalents, more preferably 1 to 3 equivalents, relative to the alcohol derivative (VIIIA).
- the reaction solvent used for the nucleophilic substitution reaction is appropriately selected depending on the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- an alcohol solvent such as methanol or ethanol, acetonitrile or Nitrile solvents such as propionitrile, aprotic polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide or dimethyl sulfoxide, ether systems such as diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-dioxane Solvent, ester solvent such as ethyl acetate or propyl acetate, chlorine solvent such as dichloromethane, chloroform or 1,2-dichloroethane, or a mixed solvent thereof, alcohol solvent such as methanol or ethanol, N, - dimethylformamide, N, N- dimethylacetamide or dimethylsulfoxide aprotic polar solvent or diethyl
- the reaction temperature of the nucleophilic substitution reaction is preferably ⁇ 20 ° C. to 200 ° C., more preferably 0 to 150 ° C.
- the reaction time of the nucleophilic substitution reaction is appropriately selected according to the reaction temperature and other conditions, but is preferably 1 to 30 hours.
- the concentration of the alcohol derivative (VIIIA) used for the nucleophilic substitution reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
- cyclohexane derivatives represented by general formula (VIIA-a) are nucleophilic using cyclohexane derivative (VIIA-b) in the presence or absence of a base as shown in Scheme 9, for example. It can be obtained by a substitution reaction or a coupling reaction. [Wherein each symbol has the same definition as above. ]
- the cyclohexane derivative (VIIA-b) can be obtained, for example, by a nucleophilic substitution reaction between a halogenated heteroaryl derivative (IX) and an alcohol derivative (VIIIA) in the presence of a base, as shown in Scheme 5 above.
- the nucleophile used for the nucleophilic substitution reaction can be purchased. Moreover, it can also manufacture by a well-known method.
- the amount of the nucleophile used for the nucleophilic substitution reaction is preferably 0.2 to 10 equivalents, more preferably 0.5 to 3 equivalents, relative to the cyclohexane derivative (VIIA-b).
- a base may be used if desired.
- the base to be used include inorganic bases such as sodium hydride, sodium hydrogen carbonate and potassium carbonate, organic bases such as triethylamine, diisopropylethylamine and pyridine, and mixtures thereof.
- the amount of base used for the nucleophilic substitution reaction is preferably 0.5 to 20 equivalents, more preferably 1 to 3 equivalents, relative to the cyclohexane derivative (VIIA-b).
- the reaction solvent used for the nucleophilic substitution reaction is appropriately selected depending on the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- an alcohol solvent such as methanol or ethanol, acetonitrile or Nitrile solvents such as propionitrile, aprotic polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide or dimethyl sulfoxide, ether systems such as diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-dioxane Solvent, ester solvent such as ethyl acetate or propyl acetate, chlorine solvent such as dichloromethane, chloroform or 1,2-dichloroethane, or a mixed solvent thereof, alcohol solvent such as methanol or ethanol, N, - dimethylformamide, N, N- dimethylacetamide or dimethylsulfoxide aprotic polar solvent or diethyl
- the reaction temperature of the nucleophilic substitution reaction is preferably ⁇ 20 ° C. to 200 ° C., more preferably 0 to 150 ° C.
- the reaction time of the nucleophilic substitution reaction is appropriately selected according to conditions such as the reaction temperature, but is preferably 1 to 60 hours.
- the concentration of the cyclohexane derivative (VIIA-b) used for the nucleophilic substitution reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
- the coupling reaction for example, a method using an organometallic compound such as an organomagnesium compound, an organozinc compound or an organoboron compound and a halide such as an aryl halide, a heteroaryl halide or an alkyl halide in the presence of a metal catalyst.
- organometallic compound such as an organomagnesium compound, an organozinc compound or an organoboron compound
- a halide such as an aryl halide, a heteroaryl halide or an alkyl halide in the presence of a metal catalyst.
- the metal catalyst and organometallic compound used for the coupling reaction can be purchased. Moreover, it can also manufacture by a well-known method or a method according to it.
- the amount of the organometallic compound used in the coupling reaction is preferably 0.5 to 20 equivalents and more preferably 1 to 3 equivalents with respect to the cyclohexane derivative (VIIA-b).
- Examples of the metal catalyst used in the coupling reaction include zero-valent palladium complex catalysts such as tetrakistriphenylphosphine palladium (0), tris (dibenzylideneacetone) dipalladium (0), and bis (dibenzylideneacetone) palladium (0). Among them, tetrakistriphenylphosphine palladium (0) is preferable.
- the amount of the metal catalyst used for the coupling reaction is preferably 0.001 to 10 equivalents, and more preferably 0.01 to 1 equivalents with respect to the cyclohexane derivative (VIIA-b).
- a base may be used if desired.
- the base to be used include inorganic bases such as sodium hydroxide or sodium carbonate, metal alkoxides such as tert-butoxy sodium or tert-butoxy potassium, carboxylates such as sodium acetate or potassium acetate, and aqueous solutions thereof.
- An inorganic base such as sodium hydroxide or sodium carbonate or an aqueous solution thereof is preferred.
- the amount of base used for the coupling reaction is preferably 0.5 to 100 equivalents, more preferably 1 to 30 equivalents, relative to the cyclohexane derivative (VIIA-b).
- the reaction solvent used for the coupling reaction is appropriately selected depending on the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- an aromatic hydrocarbon solvent such as benzene or toluene
- Alcohol solvents such as methanol or ethanol
- nitrile solvents such as acetonitrile or propionitrile
- aprotic polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide or dimethylsulfoxide, diethyl ether, tetrahydrofuran, dimethoxy
- ether solvents such as ethane or 1,4-dioxane
- ester solvents such as ethyl acetate or propyl acetate
- chlorine solvents such as dichloromethane, chloroform, or 1,2-dichloroethane, or a mixed solvent thereof.
- Benzene or aromatic solvents such as toluene, alcohol solvents methanol or ethanol, diethyl ether, tetrahydrofuran, ether solvents or a mixed solvent thereof and dimethoxyethane or 1,4-dioxane are preferred.
- the reaction temperature of the coupling reaction is preferably 0 to 300 ° C, more preferably 20 to 200 ° C.
- the reaction time for the coupling reaction is appropriately selected according to the reaction temperature and other conditions, but is preferably 1 to 48 hours.
- the concentration of the cyclohexane derivative (VIIA-b) used for the coupling reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
- the urea derivative (IA-a) in which R 4 is R 11 substituted with one morpholinyl group or (R 7 ) R 8 N— is, for example, as shown in Scheme 10
- Ureation reaction of aniline derivative (IV) with cyclohexaneamine derivative (VA) in the presence of urea agent and base (step 1) and urea derivative (IA-b) and nucleophile in the presence or absence of base It can be obtained by a nucleophilic substitution reaction (step 2) using (IX).
- each symbol has the same definition as above. ]
- the cyclohexaneamine derivative (VA) can be obtained, for example, by a deprotection reaction of the cyclohexane derivative (VI) as shown in Scheme 4 above.
- the aniline derivative (IV) used for the urea formation reaction can be produced by a known method or a method analogous thereto.
- the amount of the cyclohexaneamine derivative (VA) used for the ureaization reaction is preferably 0.5 to 10 equivalents, more preferably 1 to 3 equivalents, relative to the aniline derivative (IV).
- Examples of the urea agent used in the urea reaction include, for example, chloroformate derivatives such as 2,2,2-trichloroethyl chloroformate, phenyl chloroformate or p-nitrophenyl chloroformate, triphosgene, phosgene, N, N′— Examples include carbonyldiimidazole or N, N′-disuccinimidyl carbonate, with triphosgene being preferred.
- the amount of the urea agent used in the urea reaction is preferably from 0.1 to 100 equivalents, more preferably from 0.3 to 30 equivalents, based on the aniline derivative (IV).
- Examples of the base used in the urea reaction include organic bases such as triethylamine or diisopropylethylamine, inorganic bases such as sodium hydrogen carbonate or potassium carbonate, metal hydride compounds such as sodium hydride, potassium hydride or calcium hydride, methyl Examples thereof include alkyllithium such as lithium or butyllithium, lithium amide such as lithium hexamethyldisilazide or lithium diisopropylamide, or a mixture thereof, and an organic base such as triethylamine or diisopropylethylamine is preferable.
- organic bases such as triethylamine or diisopropylethylamine
- inorganic bases such as sodium hydrogen carbonate or potassium carbonate
- metal hydride compounds such as sodium hydride, potassium hydride or calcium hydride
- alkyllithium such as lithium or butyllithium
- lithium amide such as lithium hexamethyldisilazide or lithium diisoprop
- the amount of the base used for the urea formation reaction is preferably 1 to 100 equivalents, more preferably 2 to 30 equivalents, relative to the aniline derivative (IV).
- the reaction solvent used for the urea reaction is appropriately selected according to the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- N, N-dimethylformamide, N, N-dimethyl Aprotic polar solvents such as acetamide or dimethyl sulfoxide, ether solvents such as diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-dioxane, ester solvents such as ethyl acetate or propyl acetate, dichloromethane, chloroform or 1,2-
- chlorinated solvents such as dichloroethane, nitrile solvents such as acetonitrile or propionitrile, or mixed solvents thereof.
- Chlorine solvents such as dichloromethane, chloroform or 1,2-dichloroethane, acetonitrile or propylene. Nitriles nitrile are preferred.
- the reaction temperature of the urea reaction is preferably ⁇ 40 ° C. to 200 ° C., more preferably ⁇ 20 ° C. to 150 ° C.
- the reaction time of the urea reaction is appropriately selected according to the reaction temperature and other conditions, but is preferably 30 minutes to 30 hours.
- the concentration of the aniline derivative (IV) used for the urea formation reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
- the nucleophile (IX) used for the nucleophilic substitution reaction can be purchased. Moreover, it can also manufacture by a well-known method.
- the amount of the nucleophile (IX) used in the nucleophilic substitution reaction is preferably 0.2 to 10 equivalents, more preferably 0.5 to 3 equivalents, relative to the urea derivative (IA-b).
- a base may be used if desired.
- the base to be used include inorganic bases such as sodium hydride, sodium hydrogen carbonate and potassium carbonate, organic bases such as triethylamine, diisopropylethylamine and pyridine, and mixtures thereof.
- the amount of base used in the nucleophilic substitution reaction is preferably 0.5 to 20 equivalents, more preferably 1 to 3 equivalents, relative to the urea derivative (IA-b).
- the reaction solvent used for the nucleophilic substitution reaction is appropriately selected depending on the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction.
- an alcohol solvent such as methanol or ethanol, acetonitrile or Nitrile solvents such as propionitrile, aprotic polar solvents such as N, N-dimethylformamide, N, N-dimethylacetamide or dimethyl sulfoxide, ether systems such as diethyl ether, tetrahydrofuran, dimethoxyethane or 1,4-dioxane Solvent, ester solvent such as ethyl acetate or propyl acetate, chlorine solvent such as dichloromethane, chloroform or 1,2-dichloroethane, or a mixed solvent thereof, alcohol solvent such as methanol or ethanol, N, - dimethylformamide, N, N- dimethylacetamide or dimethylsulfoxide aprotic polar solvent or diethyl
- the reaction temperature of the nucleophilic substitution reaction is preferably ⁇ 20 ° C. to 200 ° C., more preferably 0 to 150 ° C.
- the reaction time of the nucleophilic substitution reaction is appropriately selected according to conditions such as the reaction temperature, but is preferably 1 to 60 hours.
- the concentration of the urea derivative (IA-b) used for the nucleophilic substitution reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
- the DDR1 inhibitor of the present invention is characterized by containing a urea derivative (I) or a pharmacologically acceptable salt thereof as an active ingredient.
- DDR1 inhibitor means a compound that inhibits the kinase activity of DDR1.
- the urea derivative (I) or a pharmacologically acceptable salt thereof has DDR1 inhibitory activity, it is expected as a therapeutic agent for diseases that can be expected to improve the pathological condition or relieve symptoms based on the action mechanism, for example, cancer. it can.
- “Cancer” means, for example, pharyngeal cancer, laryngeal cancer, tongue cancer, non-small cell lung cancer, breast cancer, esophageal cancer, stomach cancer, colon cancer, uterine cancer, endometrial cancer, ovarian cancer, liver cancer, pancreatic cancer, Gallbladder cancer, bile duct cancer, kidney cancer, renal pelvis and ureter cancer, bladder cancer, prostate cancer, malignant melanoma, thyroid cancer, neuroosteosarcoma, chondrosarcoma, rhabdomyosarcoma, hemangiosarcoma, fibrosarcoma, glioma, leukemia And malignant lymphoma, neuroblastoma, myeloma or brain tumor.
- the urea derivative (I) or a pharmacologically acceptable salt thereof has DDR1 inhibitory activity.
- an in vitro test for example, a method for evaluating the kinase activity of DDR1 by quantifying the phosphorylated base mass or the amount of ATP consumed (Analytical Biochemistry, 1999, Vol. 269, p. 94-104). And a method for evaluating the binding to DDR1 (Journal of Biomolecular Screening, 2009, Vol. 14, p. 924-935).
- the method for evaluating the kinase activity of DDR1 includes, for example, a method in which a purified protein of DDR1 intracellular domain, a substrate peptide, and ATP are mixed and reacted to quantify the phosphorylated substrate peptide. It is done.
- the phosphorylated substrate peptide can be quantified by measurement of fluorescence resonance energy transfer, for example, by using a substrate peptide previously labeled with biotin or a fluorescent substance.
- the commercially available compound was used.
- the solvent name shown in the NMR data indicates the solvent used for the measurement.
- the 400 MHz NMR spectrum was measured using a JNM-AL400 type nuclear magnetic resonance apparatus (JEOL Ltd.) or a JNM-ECS400 type nuclear magnetic resonance apparatus (JEOL Ltd.).
- the chemical shift is represented by ⁇ (unit: ppm) based on tetramethylsilane, and the signals are s (single line), d (double line), t (triple line), q (quadruplex line), m, respectively.
- the raw material and intermediate of urea derivative (I) were synthesized by the method described in the following reference examples.
- the commercially available compound was used about the compound which is used for the synthesis
- Example 1 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea: 1- (trans-4-((2-chloropyrimidin-4-yl) oxy) cyclohexyl) -3- (2-methoxy-5- (trifluoromethoxy) phenyl) urea (0.016 g, 0.034 mmol), A solution of morpholine (0.0032 g, 0.037 mmol) and sodium carbonate (0.068 g, 0.064 mmol) in ethanol (0.17 mL) was stirred at room temperature for 1 hour, and then the reaction solution was charged with morpholine (0.010 g, 0 .11 mmol) was added.
- Example 3 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((2- (methylamino) pyrimidin-4-yl) oxy) cyclohexyl) urea : Using a 1.0 N methylamine / THF solution (0.20 mL), 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((2-morpholinopyrimidine-4 -The title compound (0.010 g) (hereinafter referred to as the compound of Example 3) was obtained in the same manner as in the synthesis of (yl) oxy) cyclohexyl) urea (Example 1).
- the organic layer was washed sequentially with a saturated aqueous ammonium chloride solution and a saturated aqueous sodium chloride solution.
- the obtained organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a crude product.
- 10 wt% palladium-carbon 50 wt% water content, 0.10 g was added, and the mixture was stirred for 5 hours in a hydrogen atmosphere.
- the reaction solution was filtered through Celite (registered trademark), and the filtrate was concentrated under reduced pressure to obtain a crude product.
- 2,2,2-Trichloroethyl chloroformate (3.3 g, 16 mmol) was added to a THF solution of the crude product and DIPEA (3.8 mL, 22 mmol) obtained under ice cooling. After stirring overnight at room temperature, water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed sequentially with a saturated aqueous ammonium chloride solution and a saturated aqueous sodium chloride solution. The obtained organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- the organic layer was washed successively with a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution.
- the obtained organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the title compound (0.40 g).
- Example 5 (3- (Hydroxymethyl) -2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl ) Synthesis of urea: 2,2,2-Trichloroethyl (3- (hydroxymethyl) -2-methoxy-5- (pentafluorosulfanyl) phenyl) carbamate (0.033 g, 0.072 mmol) was used to give 1- (2-methoxy- In the same manner as in the synthesis of 5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea (Example 4), the title compound (0.
- Example 6 3- (hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl ) Synthesis of urea: 2,2,2-Trichloroethyl (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) carbamate (0.043 g, 0.11 mmol) was used to give 1- (2-methoxy-5 The title compound (0.025 g ) (Hereinafter referred to as the compound of Example 6).
- Example 7 1- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) -3- (2- (oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) Synthesis of urea: 2,2,2-Trichloroethyl (2- (oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) carbamate (0.044 mg, 0.11 mmol) was used to give 1- (2-methoxy-5- In the same manner as in the synthesis of (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea (Example 4), the title compound (0.049 g) (Hereinafter, the compound of Example 7) was obtained.
- Example 8 1- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) -3- (2- (3-oxopiperazin-1-yl) -5- (trifluoromethyl Synthesis of) phenyl) urea: 2,2,2-Trichloroethyl (2- (3-oxopiperazin-1-yl) -5- (trifluoromethyl) phenyl) carbamate (0.030 g, 0.069 mmol) was used to give 1- (2-methoxy In the same manner as in the synthesis of -5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea (Example 4), 0.027 g) (hereinafter referred to as the compound of Example 8).
- Example 9 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4- (pyrimidine-2-yloxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.030 g, 0.078 mmol), trans-4- (pyrimidine-2-yloxy) cyclohexaneamine (0.015 g , 0.078 mmol) of 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea
- the title compound (0.018 g) (hereinafter, the compound of Example 9) was obtained in the same manner as in (Example 4).
- Example 10 Synthesis of 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4- (pyrimidine-2-yloxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (pentafluorosulfanyl) phenyl) carbamate (0.066 g, 0.16 mmol), trans-4- (pyrimidine-2-yloxy) cyclohexaneamine (0.020 g) , 0.10 mmol) of 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea
- the title compound (0.040 g) (hereinafter, the compound of Example 10) was obtained in the same manner as in (Example 4).
- Example 11 Synthesis of 1- (2-methoxy-5- (trifluoromethyl) phenyl) -3- (trans-4- (pyrimidine-2-yloxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethyl) phenyl) carbamate (0.057 g, 0.16 mmol), trans-4- (pyrimidine-2-yloxy) cyclohexaneamine (0.020 g , 0.10 mmol) of 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea
- the title compound (0.032 g) (hereinafter, the compound of Example 11) was obtained in the same manner as in (Example 4).
- Example 12 Synthesis of 1- (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) -3- (trans-4- (pyrimidine-2-yloxy) cyclohexyl) urea: 2,2,2-trichloroethyl (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) carbamate (0.062 g, 0.16 mmol), trans-4- (pyrimidine-2-iroxy ) 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) using cyclohexaneamine (0.020 g, 0.10 mmol)
- the title compound (0.045 g) (hereinafter referred to as the compound of Example 12) was obtained.
- Example 13 Synthesis of 1- (2- (oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) -3- (trans-4- (pyrimidine-2-yloxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2- (oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) carbamate (0.063 g, 0.16 mmol), trans-4- (pyrimidine-2-yloxy) 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy using cyclohexaneamine (0.020 g, 0.10 mmol) ) Cyclohexyl)
- the title compound (0.042 g) (hereinafter, the compound of Example 13) was obtained in the same manner as in the synthesis of urea (Example 4
- Example 15 Synthesis of 1- (2- (3-oxopiperazin-1-yl) -5- (trifluoromethyl) phenyl) -3- (trans-4- (pyrimidine-2-yloxy) cyclohexyl) urea : 2,2,2-trichloroethyl (2- (3-oxopiperazin-1-yl) -5- (trifluoromethyl) phenyl) carbamate (0.068 g, 0.16 mmol), trans-4- (pyrimidine-2 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidine-4- The title compound (0.023 g) (hereinafter, the compound of Example 15) was obtained in the same manner as in the synthesis of (yl) oxy) cyclohexyl) urea (Example 4).
- Example 16 3- (hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) -3- (4-((6-phenylpyridazin-3-yl) oxy) cyclohexyl ) Synthesis of urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.040 g, 0.10 mmol), trans-4- (6-phenylpyridazin-3-yl) oxy) cyclohexane 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) using amine (0.014 g, 0.052 mmol) The title compound (0.017 g) (hereinafter, the compound of Example 16) was obtained in the same manner as in the synthesis of (cyclohexyl) urea (Exa
- Example 17 1- (3- (Hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) -3- (4-((6-phenylpyridazin-3-yl) oxy) cyclohexyl ) Synthesis of urea: 2,2,2-trichloroethyl (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) carbamate (0.041 g, 0.10 mmol), trans-4- (6-phenylpyridazine- 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidine) using 3-yl) oxy) cyclohexaneamine (0.014 g, 0.052 mmol) The title compound (0.018 g) (hereinafter referred to as the compound of Example 17) was obtained in the same manner as in the synthesis of -4-yl)
- Example 18 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4- (pyridine-3-yloxy) cyclohexyl) urea: 3-Fluoropyridine (0.062 g, 0.63 mmol), 1- (trans-4-hydroxycyclohexyl) -3- (2-methoxy-5- (trifluoromethoxy) phenyl) urea (0.20 g, 0.57 mmol) ) To give the title compound (0.012 g) (hereinafter referred to as the compound of Example 18) in the same manner as in the synthesis of tert-butyl (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) carbamate (Reference Example 67).
- Example 19 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.042 g, 0.11 mmol), trans-4- (pyridin-4-ylmethoxy) cyclohexaneamine dihydrochloride ( 0.015 g, 0.073 mmol) using 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl)
- the title compound (0.018 g) (hereinafter, the compound of Example 19) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 20 Synthesis of 1- (3- (hydroxymethyl) -5- (trifluoromethyl) phenyl) -3- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) urea: 2,2,2-trichloroethyl (3- (hydroxymethyl) -5- (trifluoromethyl) phenyl) carbamate (0.030 g, 0.08 mmol), trans-4- (pyridin-4-ylmethoxy) cyclohexaneamine 2 Using hydrochloride (0.010 g, 0.048 mmol), 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy ) Cyclohexyl) The title compound (0.017 g) (hereinafter, the compound of Example 20) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 22 Synthesis of 1- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) -3- (3- (trifluoromethyl) phenyl) urea: Using phenyl (3- (trifluoromethyl) phenyl) carbamate (0.030 g, 0.076 mmol) and trans-4- (pyridin-4-ylmethoxy) cyclohexaneamine dihydrochloride (0.010 g, 0.048 mmol) Similar to the synthesis of 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea (Example 4) The title compound (0.015 g) (hereinafter, the compound of Example 22) was obtained by the method.
- Example 23 Synthesis of 1- (4- (hydroxymethyl) -3- (trifluoromethyl) phenyl) -3- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) urea: 2,2,2-Trichloroethyl (4- (hydroxymethyl) -3- (trifluoromethyl) phenyl) carbamate (0.030 g, 0.082 mmol) and trans-4- (pyridin-4-ylmethoxy) cyclohexaneamine 2 Using hydrochloride (0.010 g, 0.048 mmol), 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy ) Cyclohexyl) The title compound (0.015 g) (hereinafter referred to as the compound of Example 23) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 24 Synthesis of 1- (2-methoxy-5- (trifluoromethyl) phenyl) -3- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethyl) phenyl) carbamate (0.030 g, 0.082 mmol) and trans-4- (pyridin-4-ylmethoxy) cyclohexaneamine dihydrochloride ( 0.010 g, 0.048 mmol) using 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl)
- the title compound (0.018 g) (hereinafter, the compound of Example 24) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 25 Synthesis of 1- (2-methyl-5- (trifluoromethyl) phenyl) -3- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methyl-5- (trifluoromethyl) phenyl) carbamate (0.030 g, 0.086 mmol) and trans-4- (pyridin-4-ylmethoxy) cyclohexaneamine dihydrochloride ( 0.010 g, 0.048 mmol) using 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl)
- the title compound (0.016 g) (hereinafter, the compound of Example 25) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 26 Synthesis of 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methyl-5- (pentafluorosulfanyl) phenyl) carbamate (0.030 g, 0.071 mmol) and trans-4- (pyridin-4-ylmethoxy) cyclohexaneamine dihydrochloride ( 0.010 g, 0.048 mmol) using 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl)
- the title compound (0.005 g) (hereinafter, the compound of Example 26) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 27 Synthesis of 1- (2-fluoro-5- (trifluoromethyl) phenyl) -3- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-fluoro-5- (trifluoromethyl) phenyl) carbamate (0.030 g, 0.085 mmol) and trans-4- (pyridin-4-ylmethoxy) cyclohexaneamine dihydrochloride ( 0.010 g, 0.048 mmol) using 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl)
- the title compound (0.017 g) (hereinafter, the compound of Example 27) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 28 Synthesis of 1- (2-morpholino-5- (trifluoromethyl) phenyl) -3- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-morpholino-5- (trifluoromethyl) phenyl) carbamate (0.032 g, 0.076 mmol) and trans-4- (pyridin-4-ylmethoxy) cyclohexaneamine dihydrochloride ( 0.016 g, 0.076 mmol) using 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl)
- the title compound (0.015 g) (hereinafter, the compound of Example 28) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 29 Synthesis of 1- (2-chloro-5- (trifluoromethyl) phenyl) -3- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-chloro-5- (trifluoromethyl) phenyl) carbamate (0.030 g, 0.081 mmol) and trans-4- (pyridin-4-ylmethoxy) cyclohexaneamine dihydrochloride ( 0.010 g, 0.048 mmol) using 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl)
- the title compound (0.015 g) (hereinafter the compound of Example 29) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 31 the title compound (0.015 g) (hereinafter referred to as Example 31) was used. Compound) was obtained.
- Example 32 In the same manner as in the synthesis of trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexaneamine (Reference Example 51), the title compound (0.015 g) (hereinafter referred to as Example 32) was used. Compound) was obtained.
- Example 33 (2-((1-Acetylazetidin-3-yl) oxy) -5- (trifluoromethyl) phenyl) -3- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl ) Synthesis of urea: 1- (2- (azetidine-3-yloxy) -5- (trifluoromethyl) phenyl) -3- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) urea (0.010 g, 0.022 mmol) and Acetic anhydride (0.01 ml) was added to a THF solution of triethylamine (0.01 ml).
- Example 34 (2-((1-Acetylpiperidin-4-yl) oxy) -5- (trifluoromethyl) phenyl) -3- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) Synthesis of urea: tert-Butyl 4- (2- (3- (trans-4- (pyridin-4-ylmethoxy) cyclohexyl) ureido) -4- (trifluoromethyl) phenoxy) piperidine-1-carboxylate (0.010 g, .0.
- Example 38 1- (2- (Oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) -3- (trans-4-((2- (pyridin-3-yl) pyrimidine-4- Synthesis of yl) oxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2- (oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) carbamate (0.020 g, 0.049 mmol) and trans-4-((2- (pyridine- 3-yl) pyrimidin-4-yl) oxy) cyclohexaneamine dihydrochloride (0.013 g, 0.049 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans The title compound (0.018 g) (hereinafter, the compound of Example 38) was obtained in the same manner as in the
- Example 39 1- (2-Methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((2- (pyridin-3-yl) pyrimidin-4-yl) oxy) cyclohexyl) Synthesis of urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.020 g, 0.052 mmol) and trans-4-((2- (pyridin-3-yl) pyrimidine- 4- (yl) oxy) cyclohexaneamine dihydrochloride (0.014 g, 0.052 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2 The title compound (0.017 g) (hereinafter referred to as the compound of Example 39) was obtained in the same manner as in the synthesis of (morpholinopyrimidin-4-
- Example 40 1- (2-Methoxy-5- (trifluoromethyl) phenyl) -3- (trans-4-((4- (pyridin-3-yl) pyrimidin-2-yl) oxy) cyclohexyl) Synthesis of urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethyl) phenyl) carbamate (0.020 g, 0.055 mmol) and trans-4-((4- (pyridin-3-yl) pyrimidine- 2-yl) oxy) cyclohexaneamine dihydrochloride (0.015 g, 0.055 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2 The title compound (0.018 g) (hereinafter referred to as the compound of Example 40) was obtained in the same manner as in the synthesis of (morpholinopyrimidin-4-y
- Example 41 1- (2- (Oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) -3- (trans-4-((4- (pyridin-3-yl) pyrimidine-2- Synthesis of yl) oxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2- (oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) carbamate (0.020 g, 0.049 mmol) and trans-4-((4- (pyridine- 3-yl) pyrimidin-2-yl) oxy) cyclohexaneamine dihydrochloride (0.013 g, 0.049 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans The title compound (0.016 g) (hereinafter, the compound of Example 41) was obtained in the same manner as in
- Example 42 (2- (azetidine-3-yloxy) -5- (trifluoromethoxy) phenyl) -3- (trans-4-((6- (methylamino) pyrimidin-4-yl) oxy Synthesis of) cyclohexyl) urea: tert-Butyl 3- (2-(((2,2,2-trichloroethyl) carbonyl) amino) -4- (trifluoromethyl) phenoxy) azetidine-1-carboxylate (0.050 g, 0.098 mmol) 6-((trans-4-aminocyclohexyl) oxy) -N-methylpyrimidin-4-amine dihydrochloride (0.022 g, 0.098 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl).
- Example 43 1- (trans-4-((6- (Methylamino) pyrimidin-4-yl) oxy) cyclohexyl) -3- (2- (piperidin-4-yloxy) -5- (trifluoromethoxy Synthesis of) phenyl) urea: tert-butyl 4- (2-(((2,2,2-trichloroethoxy) carbonyl) amino) -4- (trifluoromethyl) phenoxy) piperidine-1-carboxylate (0.050 g, 0.093 mmol) and 6-((trans-4-aminocyclohexyl) oxy) -N-methylpyrimidin-4-amine dihydrochloride (0.020 g, 0.093 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl).
- Example 44 1- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) -3- (2- (oxetane-3-yloxy) -5- (trifluoromethoxy) phenyl) Synthesis of urea: 2,2,2-Trichloroethyl (2- (oxetane-3-yloxy) -5- (trifluoromethoxy) phenyl) carbamate (0.020 g, 0.047 mmol) was used to give 1- (2-methoxy-5- In the same manner as in the synthesis of (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea (Example 4), the title compound (0.020 g) (Hereinafter, the compound of Example 44) was obtained.
- Example 45 1- (3- (Hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) -3- (trans-4-((2- (pyridin-3-yl) pyrimidine-4 Synthesis of -yl) oxy) cyclohexyl) urea: 2,2,2-Trichloroethyl (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) carbamate (0.050 g, 0.050 mmol) and trans-4-((2- (pyridine -3-yl) pyrimidin-4-yl) oxy) cyclohexaneamine dihydrochloride (0.013 g, 0.050 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- ( In the same manner as in the synthesis of trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohe
- Example 46 Synthesis of 1- (2-ethoxy-5- (trifluoromethyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea: 2,2,2-Trichloroethyl (2-ethoxy-5- (trifluoromethyl) phenyl) carbamate (0.040 g, 0.11 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) Phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea The title compound (0.026 g) (hereinafter referred to as Example) was prepared in the same manner as in the synthesis of Example 4).
- Example 47 1- (2- (Oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) -3- (trans-4-((2- (pyridin-4-yl) pyrimidine-4- Synthesis of yl) oxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2- (oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) carbamate (0.020 g, 0.049 mmol) and trans-4-((4- (pyridine- 3-yl) pyrimidin-4-yl) oxy) cyclohexaneamine dihydrochloride (0.013 g, 0.049 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans The title compound (0.010 g) (hereinafter referred to as the compound of Example 47) was obtained in the same manner
- Example 48 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((2-morpholinopyridin-4-yl) oxy) cyclohexyl) urea: 2,2,2-Trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.021 g, 0.054 mmol) and trans-4-((2-morpholinopyridin-4-yl) oxy) Cyclohexaneamine dihydrochloride (0.010 g, 0.036 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidine-4- The title compound (0.010 g) (hereinafter, the compound of Example 48) was obtained in the same manner as in the synthesis of (yl) oxy) cyclohexyl) urea (Ex
- Example 49 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4- (pyridin-4-yloxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.075 g, 0.20 mmol) and trans-4- (pyridin-4-yloxy) cyclohexaneamine dihydrochloride ( 0.025 g, 0.13 mmol) using 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl)
- the title compound (0.041 g) (hereinafter, the compound of Example 49) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 50 3- (3- (Hydroxymethyl) -2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl ) Synthesis of urea: 2,2,2-Trichloroethyl (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.046 g, 0.11 mmol) was used to give 1- (2-methoxy-5 In the same manner as in the synthesis of-(pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea (Example 4), the title compound (0.022 g ) (Hereinafter the compound of Example 50) was obtained.
- Example 53 Synthesis of 1- (4- (hydroxymethyl) -3- (trifluoromethyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea : Using 2,2,2-trichloroethyl (4- (hydroxymethyl) -3- (trifluoromethoxy) phenyl) carbamate (0.030 g, 0.082 mmol), 1- (2-methoxy-5- (pentafluoro) The title compound (0.021 g) (hereinafter referred to as “sulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea” was synthesized in the same manner as in Example 4).
- Example 54 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((4- (methylamino) pyrimidin-2-yl) oxy) cyclohexyl) urea : 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.038 g, 0.099 mmol) and 2-((trans-4-aminocyclohexyl) oxy) -N-methyl Using pyrimidine-4-amine dihydrochloride (0.017 g, 0.066 mmol), 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidine The title compound (0.023 g) (hereinafter, the compound of Example 54) was obtained in the same manner as in the synthesis (Example 4) of -4-yl) oxy
- Example 55 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.038 g, 0.099 mmol) and trans-4-((4-morpholinopyrimidin-2-yl) oxy) Cyclohexaneamine dihydrochloride (0.021 g, 0.066 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidine-4- The title compound (0.027 g) (hereinafter, the compound of Example 55) was obtained in the same manner as in the synthesis of (yl) oxy) cyclohexyl) urea (
- Example 57 Synthesis of 1- (2-morpholino-5- (trifluoromethyl) phenyl) -3- (trans-4- (pyrimidine-2-yloxy) cyclohexyl) urea: 2,2,2-Trichloroethyl (2-morpholino-5- (trifluoromethyl) phenyl) carbamate (0.042 g, 0.10 mmol) and trans-4- (pyrimidine-2-yloxy) cyclohexaneamine (0.019 g , 0.10 mmol) of 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea
- the title compound (0.021 g) (hereinafter, the compound of Example 57) was obtained in the same manner as in (Example 4).
- Example 58 Synthesis of 1- (2-chloro-5- (trifluoromethyl) phenyl) -3- (trans-4- (pyrimidine-2-yloxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-chloro-5- (trifluoromethyl) phenyl) carbamate (0.030 g, 0.081 mmol) and trans-4- (pyrimidine-2-yloxy) cyclohexaneamine (0.016 g , 0.081 mmol) of 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea
- the title compound (0.02 g) (hereinafter, the compound of Example 58) was obtained in the same manner as in the synthesis (Example 4).
- Example 59 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((6-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.037 g, 0.095 mmol), trans-4-((6-morpholinopyrimidin-4-yl) oxy) Cyclohexaneamine dihydrochloride (0.020 g, 0.064 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidine-4- The title compound (0.019 g) (hereinafter, the compound of Example 59) was obtained in the same manner as in the synthesis of (yl) oxy) cyclohexyl) ure
- Example 60 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((6- (methylamino) pyrimidin-2-yl) oxy) cyclohexyl) urea : 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.067 g, 0.17 mmol), 2-((trans-6-aminocyclohexyl) oxy) -N-methyl Pyrimidine-4-amine dihydrochloride (0.030 g, 0.12 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidine The title compound (0.035 g) (hereinafter, the compound of Example 60) was obtained in the same manner as in the synthesis (Example 4) of -4-yl) oxy)
- Example 61 1- (trans-4-((2-((2-hydroxyethyl) amino) pyrimidin-4-yl) oxy) cyclohexyl) -3- (3- (hydroxymethyl) -2-methoxy- Synthesis of 5- (trifluoromethyl) phenyl) urea: 2,2,2-trichloroethyl (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) carbamate (0.030 g, 0.076 mmol), 2-((4-((trans- 4-Aminocyclohexyl) oxy) pyrimidin-2-yl) amino) ethanol dihydrochloride (0.020 g, 0.069 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- In the same manner as in the synthesis of (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexy
- Example 62 1- (trans-4-((2-((2-hydroxyethyl) amino) pyrimidin-4-yl) oxy) cyclohexyl) -3- (2-methoxy-5- (trifluoromethoxy) Synthesis of phenyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.029 g, 0.076 mmol), 2-((4-((trans-4-aminocyclohexyl) oxy) Pyrimidin-2-yl) amino) ethanol dihydrochloride (0.020 g, 0.069 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-(( The title compound (0.013 g) (hereinafter referred to as the compound of Example 62) was obtained in the same manner as in the synthesis of 2-morpholinopyrimidin
- Example 63 1- (trans-4-((2-((2-hydroxyethyl) amino) pyrimidin-4-yl) oxy) cyclohexyl) -3- (2- (oxetane-3-yloxy) -5 Synthesis of-(trifluoromethyl) phenyl) urea: 2,2,2-trichloroethyl (2- (oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) carbamate (0.031 g, 0.076 mmol), 2-((4-((trans-4 -Aminocyclohexyl) oxy) pyrimidin-2-yl) amino) ethanol dihydrochloride (0.020 g, 0.069 mmol) with 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- ( The title compound (0.018 g) (hereinafter, the compound of Example 63) was obtained in the same manner as in the
- Example 64 1- (trans-4-((2- (methylamino) pyrimidin-4-yl) oxy) cyclohexyl) -3- (2- (oxetane-3-yloxy) -5- (trifluoromethyl Synthesis of) phenyl) urea: 2,2,2-trichloroethyl (2- (oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) carbamate (0.038 g, 0.077 mmol), 4-((trans-4-aminocyclohexyl) 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-) using oxy) -N-methylpyrimidin-2-amine dihydrochloride (0.017 g, 0.066 mmol).
- Example 65 1- (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) -3- (trans-4-((2- (methylamino) pyrimidin-4-yl) Synthesis of oxy) cyclohexyl) urea: 2,2,2-trichloroethyl (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) carbamate (0.031 g, 0.077 mmol), 4-((trans-4-aminocyclohexyl) ) Oxy) -N-methylpyrimidin-2-amine dihydrochloride (0.017 g, 0.066 mmol) to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4 The title compound (0.029 g) (hereinafter, the compound of Example 65) was obtained in the same manner as in the synthesis of-((2-morpholinopyrimidin-4-yl
- Example 66 Synthesis of 1- (2- (oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) -3- (trans-4- (pyrimidine-4-yloxy) cyclohexyl) urea: 2,2,2-Trichloroethyl (2- (oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) carbamate, trans-4- (pyrimidine-4-yloxy) cyclohexaneamine was used to give 1- (2 Title compound in the same manner as in the synthesis of Example 4) -methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) urea (0.029 g) (hereinafter, the compound of Example 66) was obtained.
- Example 68 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4- (pyridin-3-ylmethoxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.030 g, 0.079 mmol), trans-4- (pyridin-3-ylmethoxy) cyclohexaneamine dihydrochloride ( 0.020 g, 0.079 mmol) using 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl)
- the title compound (0.022 g) (hereinafter, the compound of Example 68) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 69 Synthesis of 1- (2-methoxy-5- (trifluoromethyl) phenyl) -3- (trans-4- (pyridin-3-ylmethoxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethyl) phenyl) carbamate (0.029 g, 0.079 mmol), trans-4- (pyridin-3-ylmethoxy) cyclohexaneamine dihydrochloride ( 0.020 g, 0.079 mmol) using 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl)
- the title compound (0.021 g) (hereinafter, the compound of Example 69) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 70 3- (3- (Hydroxymethyl) -2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((6- (methylamino) pyrimidin-4-yl) Synthesis of oxy) cyclohexyl) urea: 2,2,2-trichloroethyl (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.026 g, 0.064 mmol), 6-((trans-4-aminocyclohexyl) ) Oxy) -N-methylpyrimidin-4-amine dihydrochloride (0.015 g, 0.058 mmol) to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4 The title compound (0.0083 g) (hereinafter, the compound of Example 70) was obtained in the same manner as in the synthesis of-((2-morpholino
- Example 71 1- (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) -3- (trans-4-((6- (methylamino) pyrimidin-4-yl) Synthesis of oxy) cyclohexyl) urea: 2,2,2-trichloroethyl (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethyl) phenyl) carbamate (0.025 g, 0.064 mmol), 6-((trans-4-aminocyclohexyl) ) Oxy) -N-methylpyrimidin-4-amine dihydrochloride (0.015 g, 0.058 mmol) to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4 The title compound (0.0076 g) (hereinafter, the compound of Example 71) was obtained in the same manner as in the synthesis (Example 4) of — ((2-
- Example 72 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((pyridin-3-ylmethoxy) methyl) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.029 g, 0.075 mmol), trans-4-((pyridin-3-ylmethoxy) methyl) cyclohexaneamine 2 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) using hydrochloride (0.018 g, 0.068 mmol) ) Cyclohexyl) The title compound (0.018 g) (hereinafter, the compound of Example 72) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 73 Synthesis of 1- (2-methoxy-5- (trifluoromethyl) phenyl) -3- (trans-4-((pyridin-3-ylmethoxy) methyl) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethyl) phenyl) carbamate (0.028 g, 0.075 mmol), trans-4-((pyridin-3-ylmethoxy) methyl) cyclohexaneamine 2 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) using hydrochloride (0.018 g, 0.068 mmol) ) Cyclohexyl) The title compound (0.014 g) (hereinafter, the compound of Example 73) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 74 Synthesis of 1- (2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((pyridin-4-ylmethoxy) methyl) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.029 g, 0.075 mmol), trans-4-((pyridin-4-ylmethoxy) methyl) cyclohexaneamine 2 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) using hydrochloride (0.018 g, 0.068 mmol) ) Cyclohexyl) The title compound (0.017 g) (hereinafter, the compound of Example 74) was obtained in the same manner as in the synthesis of urea (Example 4
- Example 75 Synthesis of 1- (2-methoxy-5- (trifluoromethyl) phenyl) -3- (trans-4-((pyridin-4-ylmethoxy) methyl) cyclohexyl) urea: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethyl) phenyl) carbamate (0.029 g, 0.075 mmol), trans-4-((pyridin-4-ylmethoxy) methyl) cyclohexaneamine 2 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) using hydrochloride (0.018 g, 0.068 mmol) ) Cyclohexyl) The title compound (0.013 g) (hereinafter referred to as the compound of Example 75) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 76 Synthesis of 1- (2- (oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) -3- (trans-4- (pyridin-3-ylmethoxy) cyclohexyl) urea: 2,2,2-trichloroethyl (2- (oxetane-3-yloxy) -5- (trifluoromethyl) phenyl) carbamate (0.028 g, 0.069 mmol), trans-4- (pyridin-3-ylmethoxy) Cyclohexaneamine dihydrochloride (0.018 g, 0.063 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidine-4- The title compound (0.011 g) (hereinafter, the compound of Example 76) was obtained in the same manner as in the synthesis of (yl) oxy) cycl
- Example 77 Synthesis of 5-((trans-4- (3- (2-methoxy-5- (trifluoromethoxy) phenyl) ureido) cyclohexyl) methoxy) nicotinic acid amide: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.023 g, 0.060 mmol), 5-((trans-4-aminocyclohexyl) methoxy) nicotinamide 2 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) using hydrochloride (0.016 g, 0.050 mmol) The title compound (0.013 g) (hereinafter, the compound of Example 77) was obtained in the same manner as in the synthesis of () cyclohexyl) urea (Example 4
- Example 78 Synthesis of 3-((trans-4- (3- (2-methoxy-5- (trifluoromethoxy) phenyl) ureido) cyclohexyl) methoxy) benzamide: 2,2,2-trichloroethyl (2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.023 g, 0.060 mmol), 3-((trans-4-aminocyclohexyl) methoxy) benzamide hydrochloride ( 0.016 g, 0.050 mmol) using 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4-((2-morpholinopyrimidin-4-yl) oxy) cyclohexyl) The title compound (0.016 g) (hereinafter, the compound of Example 78) was obtained in the same manner as in the synthesis of urea (Example 4).
- Example 79 1- (3- (Hydroxymethyl) -2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((2- (pyridin-3-yl) pyrimidine-4 Synthesis of -yl) oxy) cyclohexyl) urea: 2,2,2-Trichloroethyl (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.020 g, 0.048 mmol) and trans-4-((2- (pyridine -3-yl) pyrimidin-4-yl) oxy) cyclohexaneamine dihydrochloride (0.013 g, 0.048 mmol) was used to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- ( In the same manner as in the synthesis of trans-4-((2-morpholinopyrimidin-4-yl) oxy)
- Example 80 1- (3- (Hydroxymethyl) -2-methoxy-5- (trifluoromethoxy) phenyl) -3- (trans-4-((2- (methylamino) pyrimidin-4-yl) Synthesis of oxy) cyclohexyl) urea: 2,2,2-trichloroethyl (3- (hydroxymethyl) -2-methoxy-5- (trifluoromethoxy) phenyl) carbamate (0.020 g, 0.048 mmol), 4-((trans-4-aminocyclohexyl) ) Oxy) -N-methylpyrimidin-2-amine dihydrochloride (0.014 g, 0.048 mmol) to give 1- (2-methoxy-5- (pentafluorosulfanyl) phenyl) -3- (trans-4 The title compound (0.019 g) (hereinafter, the compound of Example 80) was obtained in the same manner as in the synthesis of-((2-morpholinopyr
- Example 81 DDR1 inhibitory activity evaluation: The DDR1 inhibitory activity of the compounds of Examples 1 to 80 was evaluated using HTRF® KinEASE-TK kit (Cisbio Bioassays).
- test substance was dissolved in dimethyl sulfoxide and then used for the following evaluation.
- test substance and each reagent have MgCl 2 at 5 mmol / L, MnCl 2 at 0.5 mmol / L, DTT at 0.25 mmol / L, and Supplemental Enzyme buffer (Cisbio Bioassay) at 50 nmol / L.
- the solution was diluted with Kinase buffer (Cisbio Bioassay) prepared by adding to the solution.
- test substance final DMSO concentration 1%
- DDR1 intracellular domain final concentration 5 ng / ⁇ L
- phosphate donor ATP final concentration 25 ⁇ mol / concentration
- L substrate TK Substrate-biotin (final concentration 1000 nmol / L) (Cisbio Bioassay) were added and reacted at room temperature for 1 hour.
- TK antibody-cryptate Cisbio Bioassay
- streptavidin-XL665 Cisbio Bioassay
- Inhibition rate (%) ([Ratio without test substance] ⁇ [Ratio with test substance]) / ([Ratio without test substance] ⁇ [Ratio without DDR1 intracellular domain and without test substance]) ⁇ 100
- the calculated inhibition rate was returned to sigmoid dose-response using Prism 5.04 (GraphPad Software, Inc), and the IC 50 value of the test substance was calculated.
- the IC 50 value of each test substance is shown in Table 2. As is apparent from the results of Table 2-1, Table 2-2, and Table 2-3, it is shown that the urea derivative (I) of the present invention or a pharmacologically acceptable salt thereof has a high DDR1 inhibitory activity. It was done.
- urea derivative (I) and pharmacologically acceptable salt thereof of the present invention have high DDR1 inhibitory activity, they can be used as inhibitors of DDR1.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
R2は、それぞれ独立して、水素原子、又は、一つの水酸基若しくは一つの環構成原子数4~6の飽和ヘテロシクリル基で置換されていてもよいメチル基を表し、
R3は、水素原子、ハロゲン原子、炭素数1~3のアルキル基、オキソ基を有していてもよい環構成原子数4~6の飽和ヘテロシクリル基又はR5O-を表し、
R4は、一つのR6で置換されていてもよい、フェニル基、ピリジル基、ピリダジニル基又はピリミジニル基を表し、
m及びnは、それぞれ独立して、0又は1を表し、
R5は、炭素数1~3のアルキル基、又は、環構成原子数4~6の飽和ヘテロシクリル基を表し(ただし、R5の環構成原子が窒素原子である場合、すなわち、R5の環構成原子が窒素原子を含む場合は、上記窒素原子がアセチル基で置換されていてもよい。)、
R6は、カルバモイル基、フェニル基、環構成原子数5若しくは6のヘテロアリール基、環構成原子数4~6の飽和ヘテロシクリル基又は(R7)R8N-を表し、
R7及びR8は、それぞれ独立して、水素原子、又は、水酸基で置換されていてもよい炭素数1~3のアルキル基を表す(ただし、m及びnが0であり、かつ、R4がカルバモイル基で置換されている、フェニル基又はピリジル基である場合を除く。)。]
R3は、水素原子、モルホリニル基、2-オキソピペラジニル基又はR5O-であり、
R4は、一つのR6で置換されていてもよい、ピリジル基又はピリミジニル基であり、
R5は、炭素数1~3のアルキル基、3-オキセタニル基、又は、窒素原子がアセチル基で置換されていてもよい、3-アゼチジニル基、3-ピロリジニル基若しくは4-ピペリジニル基であり、
R6は、カルバモイル基、ピリジル基、モルホリニル基又は(R7)R8N-であることが好ましい。
m及びnは、0であることがより好ましい。
m及びnは、一方が0で、他方が1であることもより好ましい。
R2は、それぞれ独立して、水素原子、又は、一つの水酸基若しくは一つの環構成原子数4~6の飽和ヘテロシクリル基で置換されていてもよいメチル基を表し、
R3は、水素原子、ハロゲン原子、炭素数1~3のアルキル基、オキソ基を有していてもよい環構成原子数4~6の飽和ヘテロシクリル基又はR5O-を表し、
R4は、一つのR6で置換されていてもよい、フェニル基、ピリジル基、ピリダジニル基又はピリミジニル基を表し、
m及びnは、それぞれ独立して、0又は1を表し、
R5は、炭素数1~3のアルキル基、又は、環構成原子数4~6の飽和ヘテロシクリル基を表し(ただし、R5の環構成原子が窒素原子である場合、すなわち、R5の環構成原子が窒素原子を含む場合は、上記窒素原子がアセチル基で置換されていてもよい。)、
R6は、カルバモイル基、フェニル基、環構成原子数5若しくは6のヘテロアリール基、環構成原子数4~6の飽和ヘテロシクリル基又は(R7)R8N-を表し、
R7及びR8は、それぞれ独立して、水素原子、又は、水酸基で置換されていてもよい炭素数1~3のアルキル基を表す(ただし、m及びnが0であり、かつ、R4がカルバモイル基で置換されている、フェニル基又はピリジル基である場合を除く。)。]
上記のシクロヘキサンアミン誘導体(VA)は、例えば、上記スキーム4に示すように、シクロヘキサン誘導体(VI)の脱保護反応により得ることができる。
求核置換反応に用いる求核剤(IX)は、購入することができる。また、公知の方法で製造することもできる。
1H-NMR(400MHz,CDCl3)δ(ppm):1.12-1.21(2H,m),1.33-1.44(11H,m),1.97-2.01(4H,m),3.40-3.43(1H,m),3.60-3.61(1H,m),4.33-4.35(1H,m).
tert-ブチル trans-(4-((2-クロロピリミジン-4-イル)オキシ)シクロヘキシル)カルバマート
1H-NMR(400MHz,CDCl3)δ(ppm):1.34(2H,t,J=11.7Hz),1.45(11H,s),2.09-2.13(4H,m),3.50-3.53(1H,m),4.40-4.43(1H,m),5.07-5.09(1H,m),6.59(1H,d,J=6.3Hz),8.26(1H,d,J=6.3Hz).
tert-ブチル trans-(4-((4-クロロピリミジン-2-イル)オキシ)シクロヘキシル)カルバマート
1H-NMR(400MHz,CDCl3)δ(ppm):1.31-1.36(2H,m),1.44-1.46(9H,m),1.63-1.66(2H,m),2.10-2.16(4H,m),3.53(1H,brs),4.40(1H,brs),4.93-4.98(1H,m),6.95(1H,d,J=5.1Hz),8.36(1H,d,J=5.1Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.35-1.40(2H,m),1.58-1.68(2H,m),2.16-2.18(4H,m),3.76-3.80(1H,m),3.88(3H,s),4.47(1H,d,J=7.6Hz),5.08-5.14(1H,m),6.61(1H,d,J=5.9Hz),6.79-6.81(3H,m),8.14(1H,s),8.27(1H,d,J=5.9Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.24-1.39(2H,m),1.59-1.64(2H,m),2.15-2.17(4H,m),3.75(9H,brs),3.87(3H,s),4.52-4.54(1H,m),4.93-4.96(1H,m),5.97(1H,d,J=5.6Hz),6.79-6.81(3H,m),8.06(1H,d,J=5.6Hz),8.13(1H,s).
MS(ESI)[M+H]+:512.
1H-NMR(400MHz,CDCl3)δ(ppm):1.35-1.42(2H,m),1.56-1.66(2H,m),2.15-2.19(4H,m),3.76-3.80(1H,m),3.88(3H,s),4.45-4.49(1H,m),5.07-5.11(1H,m),6.68(1H,d,J=6.0Hz),6.79-6.82(3H,m),8.14(1H,s),8.40(1H,d,J=6.0Hz),8.74(1H,s).
MS(ESI)[M+H]+:425.
1H-NMR(400MHz,CD3OD)δ(ppm):1.37-1.40(2H,m),1.58-1.61(2H,m),2.06-2.15(4H,m),2.88(3H,s),3.61-3.64(1H,m),3.90(3H,s),4.59(1H,brs),5.06(1H,brs),5.97(1H,d,J=5.9Hz),6.80(1H,dd,J=9.1,2.6Hz),6.96(1H,d,J=8.8Hz),7.91(1H,d,J=5.9Hz),8.09(1H,d,J=2.9Hz).
MS(ESI)[M+H]+:456.
1H-NMR(400MHz,CDCl3)δ(ppm):4.15(3H,s),8.33(1H,d,J=2.2Hz),8.35(1H,d,J=2.4Hz),10.43(1H,s).
1H-NMR(400MHz,CDCl3)δ(ppm):2.01(1H,t,J=5.9Hz),3.98(3H,s),4.87(2H,d,J=5.9Hz),8.01(1H,d,J=1.8Hz),8.06(1H,d,J=1.8Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.96(1H,s),3.83(3H,s),3.97(2H,s),4.74(2H,s),6.95(1H,d,J=1.4Hz),7.04(1H,s).
MS(ESI)[M+H]+:222.
1H-NMR(400MHz,CDCl3)δ(ppm):1.90(1H,t,J=6.1Hz),3.89(3H,s),4.80(2H,d,J=5.9Hz),4.87(2H,s),7.43(1H,s),7.46(1H,d,J=1.4Hz),8.37(1H,s).
1H-NMR(400MHz,CDCl3)δ(ppm):4.11(3H,s),7.95-7.97(2H,m),10.40(1H,t,J=3.5Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):2.01(1H,t,J=5.9Hz),3.94(3H,s),4.84(2H,d,J=5.6Hz),7.64-7.67(2H,m).
1H-NMR(400MHz,CDCl3)δ(ppm):1.97(1H,t,J=6.2Hz),3.79(3H,s),3.92(2H,s),4.69(2H,d,J=6.3Hz),6.56(1H,s),6.62(1H,s).
1H-NMR(400MHz,CDCl3)δ(ppm):1.89(1H,t,J=6.0Hz),3.84(3H,s),4.77(2H,d,J=5.9Hz),4.86(2H,s),7.05(1H,s),7.40(1H,s),8.00(1H,s).
1H-NMR(400MHz,CDCl3)δ(ppm):3.85(3H,s),6.91(2H,d,J=9.6Hz),7.68(2H,d,J=9.6Hz).
MS(ESI)[M+H]+:235.
1H-NMR(400MHz,CDCl3)δ(ppm):4.02(3H,s),7.04-7.08(1H,m),7.90-7.95(1H,m),8.22-8.24(1H,m),10.5(1H,s).
MS(ESI)[M+H]+:263.
1H-NMR(400MHz,CDCl3)δ(ppm):4.15(3H,s),8.43-8.47(2H,m),10.4(1H,s).
MS(ESI)[M+H]+:308.
1H-NMR(400MHz,CDCl3)δ(ppm):3.97(3H,s),4.82-4.87(2H,m),8.12-8.21(2H,m).
MS(ESI)[M+H]+:310.
1H-NMR(400MHz,CDCl3)δ(ppm):3.82(3H,s),3.94-4.02(2H,m),4.71-4.74(2H,m),7.08-7.12(1H,m),7.16-7.20(1H,m).
MS(ESI)[M+H]+:280.
1H-NMR(400MHz,CDCl3)δ(ppm):3.88(3H,s),4.77-4.88(4H,m),7.37-7.47(1H,m),7.59-7.62(1H,m),8.46-8.58(1H,m).
MS(ESI)[M+H]+:455.
1H-NMR(400MHz,CDCl3)δ(ppm):3.38-3.39(2H,m),3.56-3.58(2H,m),3.91(2H,d,J=3.7Hz),7.17-7.18(1H,m),7.72-7.75(1H,m),8.11-8.13(1H,m).
1H-NMR(400MHz,CDCl3)δ(ppm):3.22-3.23(2H,m),3.47-3.50(2H,m),3.68(2H,s),4.09(1H,s),5.95(1H,s),6.97(1H,s),7.01(2H,s).
1H-NMR(400MHz,CDCl3)δ(ppm):3.18-3.20(2H,m),3.53-3.55(2H,m),3.67(2H,s),4.88(2H,s),6.01(1H,s),7.21-7.24(1H,m),7.38(1H,d,J=8.3Hz),7.79(1H,s),8.40(1H,s).
1H-NMR(400MHz,CDCl3)δ(ppm):4.83(2H,dd,J=8.3,5.1Hz),4.88(2H,s),5.05(2H,dd,J=7.7,6.7Hz),5.29-5.35(1H,m),6.49(1H,d,J=8.5Hz),7.29(1H,d,J=2.0Hz),7.46(1H,s),8.47(1H,s).
MS(ESI)[M+H]+:408.
1H-NMR(400MHz,CDCl3)δ(ppm):7.71(1H,d,J=8.6Hz),7.92(1H,dd,J=8.6,2.7Hz),8.31(1H,d,J=2.7Hz).
1H-NMR(400MHz,CD3OD)δ(ppm):4.72-4.75(2H,m),5.03-5.07(2H,m),5.52-5.57(1H,m),7.06(1H,d,J=9.1Hz),8.04(1H,dd,J=9.1,2.8Hz),8.39(1H,d,J=2.8Hz).
MS(ESI)[M+H]+:322.
1H-NMR(400MHz,CDCl3)δ(ppm):4.03(2H,brs),4.76-4.79(2H,m),4.99-5.03(2H,m),5.24-5.29(1H,m),6.30(1H,d,J=8.8Hz),7.05(1H,dd,J=8.8,2.7Hz),7.12(1H,d,J=2.7Hz).
MS(ESI)[M+H]+:292.
1H-NMR(400MHz,CDCl3)δ(ppm):4.82(2H,dd,J=8.3,4.9Hz),4.88(2H,s),5.03-5.07(2H,m),5.30-5.35(1H,m),6.45(1H,d,J=9.0Hz),7.42(1H,dd,J=9.0,2.7Hz),8.66(1H,s).
MS(ESI)[M+H]+:466.
1H-NMR(400MHz,CDCl3)δ(ppm):4.04(3H,s),7.16(1H,d,J=9.3Hz),7.94(1H,dd,J=9.3,2.7Hz),8.29(1H,d,J=2.7Hz).
MS(ESI)[M+H]+:280.
1H-NMR(400MHz,CDCl3)δ(ppm):3.90(3H,s),6.75(1H,d,J=9.1Hz),7.09(1H,d,J=2.7Hz),7.13(1H,dd,J=9.1,2.7Hz).
MS(ESI)[M+H]+:250.
1H-NMR(400MHz,CDCl3)δ(ppm):3.92(3H,s),4.85(2H,s),6.86-6.91(2H,m),7.51(1H,d,J=8.0Hz),8.08(1H,s).
MS(ESI)[M+H]+:382.
1H-NMR(400MHz,CDCl3)δ(ppm):3.97(3H,s),4.86(2H,s),6.95(1H,d,J=8.5Hz),7.33(1H,dd,J=8.9,1.8Hz),7.52(1H,s),8.42(1H,s).
MS(ESI)[M-tBu]+:335.
MS(ESI)[M+H]+:437.
MS(ESI)[M+H]+:534.
MS(ESI)[M-tBu]+:307.
MS(ESI)[M-tBu]+:321.
MS(ESI)[M-tBu]+:321.
MS(ESI)[M-tBu]+:277.
MS(ESI)[M-tBu]+:291.
MS(ESI)[M-tBu]+:291.
MS(ESI)[M-tBu]+:451.
MS(ESI)[M-Boc]+:421.
MS(ESI)[M-Boc]+:421.
MS(ESI)[M+H]+:349.
MS(ESI)[M+H]+:354.
MS(ESI)[M+H]+:505.
MS(ESI)[M+H]+:424
1H-NMR(400MHz,CDCl3)δ(ppm):1.25-1.46(13H,m),2.10(4H,m),3.50(1H,brs),3.74-3.78(8H,m),4.41(1H,brs),4.92(1H,brs),5.96(1H,d,J=5.6Hz),8.05(1H,d,J=5.6Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.24-1.31(2H,m),1.42(9H,s),1.60-1.64(2H,m),2.07-2.15(4H,m),3.51(1H,brs),4.39(1H,brs),4.89-4.94(1H,m),6.86(1H,t,J=4.8Hz),8.46(2H,d,J=4.8Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.33-1.36(2H,m),1.46(9H,s),1.61-1.64(2H,m),2.08-2.11(2H,m),2.29-2.31(2H,m),3.55(1H,brs),4.43(1H,brs),5.33(1H,brs),6.98(1H,d,J=9.3Hz),7.48-7.50(3H,m),7.78(1H,d,J=9.5Hz),8.00-8.02(2H,m).
1H-NMR(400MHz,CDCl3)δ(ppm):1.24-1.34(2H,m),1.48-1.55(2H,m),1.95-1.97(2H,m),2.12-2.15(2H,m),2.79-2.84(1H,m),3.75(8H,s),4.90-4.98(1H,m),5.95(1H,d,J=5.6Hz),8.05(1H,d,J=5.6Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.20-1.32(2H,m),1.55-1.60(2H,m),1.90-1.93(2H,m),2.14-2.16(2H,m),2.76-2.78(1H,m),4.92-4.94(1H,m),6.86(1H,t,J=4.8Hz),8.46(2H,d,J=4.9Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.32-1.35(2H,m),1.53-1.56(2H,m),1.94-1.97(2H,m),2.30-2.33(2H,m),2.80(1H,brs),5.33(1H,brs),6.98(1H,d,J=9.0Hz),7.47-7.50(3H,m),7.78(1H,d,J=9.0Hz),8.00-8.03(2H,m).
1H-NMR(400MHz,CDCl3)δ(ppm):1.25-1.30(2H,m),1.43-1.46(2H,m),1.45(9H,s),2.06-2.15(4H,m),2.94(3H,d,J=4.9Hz),3.50(1H,brs),4.39(1H,brs),4.85-4.91(1H,m),5.97(1H,,d,J=5.9Hz),7.96(1H,d,J=5.9Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.25-1.28(2H,m),1.43-1.46(11H,m),2.05-2.17(4H,m),3.50(1H,brs)3.59-3.61(4H,m),3.75-3.76(4H,m),4.39(1H,brs),4.87(1H,brs),6.13(1H,d,J=6.1Hz),8.02(1H,d,J=6.1Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.29-1.32(2H,m),1.44-1.46(11H,m),2.05-2.13(4H,m),3.50(1H,s),4.42(1H,s),5.06(1H,s),6.71(1H,d,J=1.0Hz),8.53(1H,d,J=0.7Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.17-1.35(2H,m),1.41-1.48(11H,m),2.07-2.10(4H,m),3.52-3.56(4H,m),3.74-3.58(4H,m),4.41(1H,brs),4.98(1H,brs),5.76(1H,s),8.29(1H,s).
1H-NMR(400MHz,CDCl3)δ(ppm):1.30-1.32(2H,m),1.43-1.47(11H,m),2.07-2.11(4H,m),2.87(3H,d,J=5.1Hz),3.50(1H,brs),4.42(1H,brs),4.83(1H,brs),4.99(1H,brs),5.60(1H,d,J=0.7Hz),8.20(1H,s).
1H-NMR(400MHz,CDCl3)δ(ppm):1.25-1.29(2H,m),1.45(9H,s),1.51-1.55(2H,m),2.08-2.12(4H,m),2.96(3H,d,J=5.1Hz),3.49(1H,brs),4.40(1H,brs),4.92(1H,brs),5.94(1H,d,J=5.9Hz),8.00(1H,d,J=5.6Hz).
MS(ESI)[M+H]+:307.
MS(ESI)[M+H]+:207.
1H-NMR(400MHz,CDCl3)δ(ppm):1.13-1.16(2H,m),1.42-1.46(11H,s),2.05-2.06(4H,m),3.33(1H,brs),3.45(1H,brs),4.37(1H,brs),4.55(2H,s),7.25-7.28(1H,m),7.68(1H,d,J=8.0Hz),8.54-8.56(2H,m).
1H-NMR(400MHz,CDCl3)δ(ppm):1.03-1.11(4H,m),1.44(9H,s),1.53-1.57(1H,m),1.83-1.86(2H,m),2.02-2.04(2H,m),3.29-3.30(2H,m),3.38-3.41(1H,m),4.37(1H,brs),4.50(2H,brs),7.28-7.29(1H,m),7.66(1H,d,J=8.0Hz),8.53-8.55(2H,m).
1H-NMR(400MHz,CDCl3)δ(ppm):1.07-1.16(4H,m),1.44(9H,s),1.53-1.57(1H,m),1.85-1.87(2H,m),2.03-2.05(2H,m),3.31(2H,d,J=6.6Hz),3.39(1H,brs),4.38(1H,brs),4.50(2H,s),7.24(2H,dd,J=3.4,2.7Hz),8.56(2H,dd,J=4.4,1.5Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.13-1.24(4H,m),1.45(9H,s),1.76-1.80(1H,m),1.94-1.96(2H,m),2.06-2.09(2H,m),3.42(1H,brs),3.84(2H,d,J=6.3Hz),3.95(3H,s),4.41(1H,brs),7.73-7.73(1H,m),8.45(1H,d,J=2.9Hz),8.81(1H,d,J=1.5Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.14-1.19(4H,m),1.45(9H,s),1.76-1.80(1H,m),1.93-1.96(2H,m),2.08-2.11(2H,m),3.42(1H,brs),3.86(2H,d,J=6.3Hz),4.41(1H,brs),7.66(1H,s),8.43(1H,d,J=2.9Hz),8.53(1H,d,J=1.7Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.12-1.20(4H,m),1.45(9H,s),1.76(1H,brs),1.94-1.96(2H,m),2.06-2.08(2H,m),3.42(1H,brs),3.80(2H,d,J=6.3Hz),3.91(3H,s),4.40(1H,brs),7.07(1H,dt,J=8.3,1.2Hz),7.33(1H,t,J=7.9 Hz),7.52(1H,t,J=2.0Hz),7.61(1H,dt,J=7.6,1.2Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.12-1.22(4H,m),1.76(1H,s),1.94(2H,d,J=8.5Hz),2.08(2H,s),3.42(1H,s),3.81(2H,d,J=6.3Hz),4.41(1H,s),5.58(1H,s),6.02(1H,s),7.03-7.06(1H,m),7.31-7.34(3H,m).
MS(ESI)[M+H]+:327.
MS(ESI)[M+H]+:378.
MS(ESI)[M+H]+:278.
MS(ESI)[M+H]+:293.
MS(ESI)[M+H]+:193.
MS(ESI)[M+H]+:371.
MS(ESI)[M+H]+:371.
MS(ESI)[M+H]+:371.
MS(ESI)[M+H]+:247.
MS(ESI)[M+H]+:421.
MS(ESI)[M+H]+:221.
MS(ESI)[M+H]+:371.
MS(ESI)[M+H]+:367.
MS(ESI)[M+H]+:221.
MS(ESI)[M+H]+:371.
MS(ESI)[M+H]+:367.
1H-NMR(400MHz,CDCl3)δ(ppm):1.34-1.36(2H,m),1.59-1.62(2H,m),2.16-2.18(4H,m),3.74-3.77(9H,m),3.93(3H,s),4.46(1H,d,J=7.8Hz),4.95(1H,brs),5.97(1H,d,J=5.6Hz),6.76(1H,s),6.85(1H,d,J=9.0Hz),7.37(1H,dd,J=9.0,2.7Hz),8.06(1H,d,J=5.6Hz),8.69(1H,d,J=2.7Hz).
MS(ESI)[M+H]+:554.
1H-NMR(400MHz,CD3OD)δ(ppm):1.21-1.42(4H,m),1.96-1.99(4H,m),3.89(3H,s),6.79(1H,ddd,J=8.8,2.9,0.9Hz),6.95(1H,d,J=8.8Hz),8.07(1H,dd,J=2.9,1.0Hz).
MS(ESI)[M+H]+:349.
1H-NMR(400MHz,CDCl3)δ(ppm):1.36-1.38(2H,m),1.61-1.63(2H,m),1.89(1H,t,J=6.1Hz),2.17-2.19(4H,m),3.74-3.77(9H,m),3.84(3H,s),4.55(1H,d,J=7.1Hz),4.77(2H,d,J=6.1Hz),4.96(1H,brs),5.98(1H,d,J=5.9Hz),6.69(1H,s),7.50(1H,d,J=2.7Hz),8.06(1H,d,J=5.6Hz),8.59(1H,d,J=2.7Hz).
MS(ESI)[M+H]+:584.
1H-NMR(400MHz,CDCl3)δ(ppm):1.36-1.39(2H,m),1.61-1.64(2H,m),1.90(1H,t,J=6.0Hz),2.17-2.19(4H,m),3.74-3.76(9H,m),3.84(3H,s),4.59(1H,d,J=7.6Hz),4.77(2H,d,J=5.9Hz),4.96(1H,brs),5.97(1H,d,J=5.6Hz),6.74(1H,s),7.35(1H,d,J=2.0Hz),8.06(1H,d,J=5.6Hz),8.39(1H,d,J=2.0Hz).
MS(ESI)[M+H]+:526.
1H-NMR(400MHz,CDCl3)δ(ppm):1.36-1.41(2H,m),1.59-1.65(2H,m),2.17-2.20(4H,m),3.75(9H,s),4.65-4.78(3H,m),4.95-4.98(1H,m),5.04(2H,t,J=6.8Hz),5.26-5.32(1H,m),5.98(1H,d,J=5.6Hz),6.44(1H,d,J=8.5Hz),6.85(1H,s),7.17(1H,d,J=8.5Hz),8.06(1H,d,J=5.9Hz),8.54(1H,d,J=2.0Hz).
MS(ESI)[M+H]+:538.
1H-NMR(400MHz,CDCl3)δ(ppm):1.38-1.40(2H,m),1.55-1.57(2H,m),2.16-2.18(4H,m),3.19(2H,t,J=5.5Hz),3.53(2H,brs),3.58(2H,s),3.75(9H,s),4.96(1H,brs),5.97-5.98(2H,m),7.46(1H,s),8.06-8.07(2H,m),8.56(1H,s).
MS(ESI)[M+H]+:564.
1H-NMR(400MHz,CDCl3)δ(ppm):1.36-1.39(2H,m),1.71-1.74(2H,m),2.17-2.20(4H,m),3.78(1H,brs),3.87(3H,s),4.48(1H,brs),4.97(1H,brs),6.79(3H,brs),6.91(1H,brs),8.15(1H,brs),8.50(2H,brs).
MS(ESI)[M+H]+:425.
1H-NMR(400MHz,CDCl3)δ(ppm):1.35-1.38(2H,m),1.66-1.75(2H,m),2.16-2.19(4H,m),3.76-3.77(1H,m),3.90(3H,s),4.47(1H,d,J=7.8Hz),4.92-4.94(1H,m),6.76(1H,s),6.81(1H,d,J=9.3Hz),6.88(1H,t,J=4.8Hz),7.34(1H,dd,J=8.9,2.8Hz),8.47(2H,d,J=4.9Hz),8.68(1H,d,J=2.7Hz).
MS(ESI)[M+H]+:469.
1H-NMR(400MHz,CDCl3)δ(ppm):1.34-1.37(2H,m),1.68-1.71(2H,m),2.15-2.18(4H,m),3.76(1H,s),3.89(3H,s),4.45(1H,brs),4.94(1H,brs),6.79(1H,brs),6.87-6.88(2H,m),7.20-7.21(1H,m),8.46-8.48(3H,m).
1H-NMR(400MHz,CDCl3)δ(ppm):1.35-1.38(2H,m),1.68-1.71(2H,m),1.92(1H,brs),2.16-2.20(4H,m),3.74(1H,brs),3.82(3H,s),4.58(1H,brs),4.74(2H,d,J=5.6Hz),4.94(1H,brs),6.74(1H,s),6.88(1H,t,J=4.9Hz),7.30-7.33(1H,m),8.39(1H,d,J=1.7Hz),8.47-8.48(2H,m).
MS(ESI)[M+H]+:439.
1H-NMR(400MHz,CDCl3)δ(ppm):1.41-1.44(2H,m),1.71-1.73(2H,m),2.21-2.24(4H,m),3.80(1H,s),4.58(1H,d,J=7.3Hz),4.78(2H,dd,J=8.3,4.9Hz),5.03-5.05(3H,m),5.29-5.30(1H,m),6.44(1H,d,J=8.3Hz),6.81(1H,brs),6.91(1H,t,J=4.8Hz),7.17(1H,d,J=6.8Hz),8.50(2H,d,J=4.6Hz),8.56(1H,d,J=1.7Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.40-1.42(2H,m),1.72-1.75(2H,m),2.21-2.23(4H,m),4.57(1H,d,J=7.3Hz),4.76-4.78(2H,m),5.03-5.05(3H,m),5.30(1H,brs),6.40(1H,d,J=9.5Hz),6.77(1H,s),6.91(1H,t,J=4.8Hz),7.31(1H,dd,J=9.0,2.7Hz),8.50(2H,d,J=4.9Hz),8.77(1H,d,J=2.7Hz).
MS(ESI)[M-H]-:509.
1H-NMR(400MHz,CD3OD)δ(ppm):1.42-1.45(2H,m),1.65-1.69(2H,m),2.11-2.21(4H,m),3.19(2H,t,J=5.2Hz),3.49(2H,t,J=5.5Hz),3.53(2H,s),3.67(1H,s),5.04(1H,d,J=3.9Hz),7.06(1H,t,J=4.9Hz),7.30(2H,dd,J=26.8,8.3Hz),8.46(1H,d,J=2.2Hz),8.54(2H,d,J=4.9Hz).
MS(ESI)[M+H]+:479.
1H-NMR(400MHz,CDCl3)δ(ppm):1.41-1.44(2H,m),1.65-1.68(2H,m),2.17-2.21(2H,m),2.33-2.37(2H,m),3.82(1H,brs),3.87(3H,s),4.53(1H,d,J=7.2Hz),5.33-5.36(1H,m),6.80-6.82(2H,m),7.01(1H,d,J=9.1Hz),7.47-7.50(3H,m),7.80(1H,d,J=9.1Hz),8.00-8.02(2H,m),8.17(1H,s).
MS(ESI)[M-H]-:501.
1H-NMR(400MHz,CD3OD)δ(ppm):1.43-1.46(2H,m),1.66-1.69(2H,m),2.07-2.10(2H,m),2.24-2.27(2H,m),3.77-3.79(4H,m),4.68(2H,s),5.22-5.26(1H,m),7.18(1H,d,J=9.3Hz),7.33(1H,s),7.47-7.49(4H,m),7.92-7.94(2H,m),8.01(1H,d,J=9.3Hz),8.39(1H,s).
1H-NMR(400MHz,CDCl3)δ(ppm):1.22-1.37(2H,m),1.60-1.69(2H,m),2.16-2.18(4H,m),3.77-3.80(1H,m),3.85(3H,s),4.22-4.25(1H,m),4.70(1H,brs),6.78-6.81(2H,m),6.89-6.91(1H,m),7.20-7.21(2H,m),8.15(1H,s),8.20(1H,dd,J=3.9,2.0Hz),8.29(1H,d,J=2.2Hz).
MS(ESI)[M+H]+:426.
1H-NMR(400MHz,CD3OD)δ(ppm):1.10-1.30(2H,m),1.40-1.50(2H,m),2.00-2.20(4H,m),3.40-3.50(1H,m),3.55-3.65(1H,m),3.89(3H,s),4.63(2H,s),6.79(1H,d,J=8.0Hz),6.95(1H,dd,J=8.0,4.0Hz),7.41(2H,bs),8.07(1H,s),8.47(2H,bs).
MS(ESI)[M+H]+:440.
1H-NMR(400MHz,CD3OD)δ(ppm):1.20-1.30(2H,m),1.40-1.50(2H,m),2.00-2.20(4H,m),3.40-3.50(1H,m),3.55-3.65(1H,m),4.61(2H,s),4.64(2H,s),7.23(1H,s),7.43(2H,d,J=8.0Hz),7.47(1H,s),7.73(1H,s),8.47(1H,d,J=8.0,4.0Hz).
MS(ESI)[M+H]+:424.
1H-NMR(400MHz,CD3OD)δ(ppm):1.25-1.40(2H,m),1.45-1.55(2H,m),2.00-2.20(4H,m),3.40-3.50(1H,m),3.55-3.65(1H,m),4.64(2H,s),4.72(2H,s),7.36(1H,d,J=4.0Hz),7.43(2H,d,J=4.0Hz),8.41(1H,d,J=4.0Hz),8.47(2H,dd,J=8.0,4.0Hz).
MS(ESI)[M+H]+:454.
1H-NMR(400MHz,CD3OD)δ(ppm):1.20-1.40(2H,m),1.40-1.50(2H,m),2.00-2.20(4H,m),3.40-3.50(1H,m),3.55-3.65(1H,m),4.64(2H,s),7.06(1H,d,J=8.0Hz),7.22(1H,d,J=8.0Hz),7.43(3H,bs),7.48(1H,d,J=8.0Hz),7.81(1H,s),8.47(2H,dd,J=8.0,4.0Hz).
MS(ESI)[M+H]+:394.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.10-1.40(4H,m),2.00-2.20(4H,m),1.90-1.92(2H,m),2.00-2.10(2H,m),3.30-3.40(1H,m),3.45-3.55(1H,m),4.57(4H,bs),5.31(1H,t,J=8.0Hz),6.16(1H,d,J=8.0Hz),7.32(2H,d,J=4.0Hz),7.47(1H,d,J=8.0Hz),7.58(1H,d,J=8.0Hz),7.91(1H,s),8.52(2H,dd,J=8.0,4.0Hz),8.61(1H,s).
MS(ESI)[M+H]+:424.
1H-NMR(400MHz,CD3OD)δ(ppm):1.10-1.30(2H,m),1.40-1.50(2H,m),2.00-2.20(4H,m),3.40-3.50(1H,m),3.55-3.65(1H,m),3.94(3H,s),4.63(2H,s),7.06(1H,d,J=8.0Hz),7.21(1H,dd,J=8.0,4.0Hz),7.43(2H,d,J=8.0Hz),8.43(1H,s),8.47(1H,dd,J=8.0,4.0Hz).
MS(ESI)[M+H]+:424.
1H-NMR(400MHz,CD3OD)δ(ppm):1.20-1.35(2H,m),1.45-1.55(2H,m),2.00-2.20(4H,m),2.29(3H,s),3.40-3.50(1H,m),3.55-3.65(1H,m),4.64(2H,s),7.06(1H,d,J=8.0Hz),7.20(1H,d,J=8.0Hz),7.31(1H,d,J=8.0Hz),7.43(2H,d,J=8.0Hz),8.13(1H,s),8.47(1H,dd,J=8.0,4.0Hz).
MS(ESI)[M+H]+:408.
1H-NMR(400MHz,CD3OD)δ(ppm):1.25-1.35(2H,m),1.45-1.55(2H,m),2.00-2.20(4H,m),3.40-3.50(1H,m),3.55-3.65(1H,m),3.95(3H,s),4.63(2H,s),7.04(1H,d,J=8.0Hz),7.37(1H,dd,J=8.0,4.0Hz),7.42(2H,d,J=8.0Hz),8.47(2H,dd,J=8.0,4.0Hz),8.67(1H,bs).
MS(ESI)[M+H]+:482.
1H-NMR(400MHz,CD3OD)δ(ppm):1.20-1.35(2H,m),1.45-1.55(2H,m),2.00-2.20(4H,m),3.40-3.50(1H,m),3.55-3.65(1H,m),4.64(2H,s),7.25-7.30(2H,m),7.42(2H,d,J=8.0Hz),8.46-8.52(3H,m).
MS(ESI)[M+H]+:412.
1H-NMR(400MHz,CD3OD)δ(ppm):1.20-1.35(2H,m),1.40-1.50(2H,m),2.00-2.20(4H,m),2.80(4H,bs),3.40-3.50(1H,m),3.55-3.65(1H,m),3.88(4H,bs),4.62(2H,s),7.20(2H,d,J=8.0Hz),7.30(2H,d,J=8.0Hz),7.41(2H,d,J=8.0Hz),8.39(1H,s),8.47(2H,d,J=8.0Hz).
MS(ESI)[M+H]+:479.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.15-1.25(2H,m),1.35-1.45(2H,m),1.90-2.00(4H,m),3.40-3.50(1H,m),3.55-3.65(1H,m),4.56(2H,s),7.19(1H,d,J=8.0Hz),7.27(1H,d,J=8.0Hz),7.33(2H,d,J=4.0Hz),7.64(1H,d,J=8.0Hz),8.25(1H,s),8.53(2H,d,J=4.0Hz),8.66(1H,bs).
MS(ESI)[M+H]+:428.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.15-1.25(2H,m),1.30-1.40(2H,m),2.00-2.20(4H,m),3.30-3.40(1H,m),3.45-3.55(1H,m),3.94(3H,s),4.57(2H,s),4.61-4.65(2H,m),4.95(2H,t,J=8.0Hz),5.30-5.35(1H,m),6.65(1H,d,J=8.0Hz),6.78(1H,dd,J=8.0,4.0Hz),7.02(1H,d,J=8.0Hz),7.31(2H,d,J=8.0Hz),8.05(1H,s),8.24(1H,bs),8.52(2H,dd,J=8.0,4.0Hz).
MS(ESI)[M+H]+:565.
MS(ESI)[M+H]+:593.
1H-NMR(400MHz,CD3OD)δ(ppm):1.35-1.45(2H,m),1.48-1.58(2H,m),2.00-2.20(4H,m)3.50-3.75(2H,m),4.35(2H,dd,J=8.0,4.0Hz),4.57-4.61(2H,m),4.92(2H,s),5.25-5.30(1H,m),6.83(1H,d,J=8.0Hz),7.21(1H,dd,J=8.0,4.0Hz),8.08(2H,d,J=8.0Hz),8.51(1H,s),8.79(2H,d,J=8.0Hz).
MS(ESI)[M+H]+:465.
1H-NMR(400MHz,CD3OD)δ(ppm):1.25-1.40(2H,m),1.45-1.55(2H,m),2.00-2.20(4H,m)3.19-3.26(1H,m),3.50-3.65(2H,m),4.92(2H,dd,J=8.0,4.0Hz),7.17(1H,d,J=8.0Hz),7.23(1H,d,J=8.0Hz),8.08(2H,d,J=8.0Hz),8.43(1H,s),8.79(2H,d,J=8.0Hz).
MS(ESI)[M+H]+:493.
1H-NMR(400MHz,CD3OD)δ(ppm):1.15-1.25(2H,m),1.35-1.45(2H,m),1.81(3H,s),1.95-2.05(4H,m),3.31-3.40(1H,m),3.45-3.55(1H,m),4.00(1H,dd,J=8.0,4.0Hz),4.16(1H,dd,J=8.0,4.0Hz),4.32-4.36(1H,m),4.51(2H,s),4.50-4.60(1H,m),5.00-5.10(1H,m),6.71(1H,d,J=8.0Hz),7.10(1H,dd,J=8.0,4.0Hz),7.31(2H,d,J=8.0Hz),8.3(2H,d,J=8.0Hz),8.41(1H,s).
MS(ESI)[M+H]+:507.
1H-NMR(400MHz,CD3OD)δ(ppm):1.25-1.40(2H,m),1.45-1.50(2H,m),1.69-1.81(2H,m),1.98-2.05(10H,m),3.31-3.40(2H,m),3.50-3.60(1H,m),3.83-3.90(1H,m),4.09-4.15(1H,m),4.62(2H,s),4.75-4.80(1H,m),7.14-7.22(2H,m),7.42(2H,d,J=4.0Hz),8.45-8.50(3H,m).
MS(ESI)[M+H]+:535.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.20-1.36(4H,m),1.80-2.00(3H,m)2.80-2.95(1H,m),2.98-3.19(3H,m),4.57(2H,s),5.00(1H,bs),7.06-7.10(2H,m),7.18(1H,d,J=4.0Hz),7.32(2H,d,J=8.0Hz),7.80(1H,s),8.52(2H,d,J=4.0Hz),8.55(1H,d,J=4.0Hz).
MS(ESI)[M+H]+:479.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.10-1.40(4H,m),1.70-1.85(1H,m),1.90-1.98(2H,m),2.0-2.1(3H,m),2.75-2.82(1H,m),2.90-3.10(3H,m),4.47(2H,s),4.98(1H,bs),7.06-7.10(2H,m),7.18(1H,d,J=4.0Hz),7.32(2H,d,J=8.0Hz),7.80(1H,s),8.52(2H,d,J=4.0Hz),8.55(1H,d,J=4.0Hz).
MS(ESI)[M+H]+:479.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.40-1.50(2H,m),1.55-1.65(2H,m),1.99-2.00(2H,m),2.17-2.20(2H,m),2.75-2.82(1H,m),3.56-3.61(1H,m),3.93(3H,s),5.25-5.31(1H,m),6.92(1H,d,J=8.0Hz),7.06(1H,d,J=8.0Hz),7.14(1H,d,J=8.0Hz),7.23(1H,d,J=8.0Hz),7.57(1H,q,J=4.0Hz),8.18(1H,s),8.54(1H,d,J=4.0Hz),8.60-8.70(2H,m),8.73(1H,dd,J=8.0,4.0Hz),9.50(1H,d,J=4.0Hz).
MS(ESI)[M+H]+:488.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.40-1.50(2H,m),1.55-1.65(2H,m),1.99-2.00(2H,m),2.17-2.20(2H,m),2.75-2.82(1H,m),3.56-3.61(1H,m),4.65-4.75(2H,m),4.98(2H,t,J=8.0Hz),5.25-5.31(1H,m),5.40-5.45(1H,m),6.77(1H,d,J=8.0Hz),6.90-6.95(1H,m),7.10(1H,d,J=8.0Hz),7.17(1H,d,J=8.0Hz),7.57(1H,q,J=4.0Hz),8.15(1H,s),8.59(1H,s),8.63-8.66(2H,m),8.73(1H,dd,J=8.0,4.0Hz),9.50(1H,d,J=4.0Hz).
MS(ESI)[M+H]+:530.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.40-1.50(2H,m),1.55-1.65(2H,m),1.99-2.00(2H,m),2.17-2.20(2H,m),3.56-3.61(1H,m),3.88(3H,s),5.25-5.31(1H,m),6.84(1H,d,J=8.0Hz),6.91(1H,d,J=8.0Hz),7.03(1H,d,J=8.0Hz),7.06(1H,d,J=8.0Hz),7.57(1H,q,J=4.0Hz),8.15(1H,s),8.21(1H,d,J=4.0Hz),8.60-8.70(2H,m),8.73(1H,dd,J=8.0,4.0Hz),9.50(1H,d,J=4.0Hz).
MS(ESI)[M+H]+:504.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.35-1.45(2H,m),1.55-1.65(2H,m),1.99-2.00(2H,m),2.17-2.20(2H,m),3.56-3.61(1H,m),3.93(3H,s),5.05-5.12(1H,m),7.05(1H,d,J=8.0Hz),7.14(1H,d,J=8.0Hz),7.23(1H,d,J=8.0Hz),7.60(1H,q,J=4.0Hz),7.80(1H,d,J=4.0Hz),8.17(1H,s),8.50-8.55(2H,m),8.72(1H,d,J=8.0Hz),8.75(1H,d,J=8.0,4.0Hz),9.35(1H,d,J=4.0Hz).
MS(ESI)[M+H]+:488.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.40-1.50(2H,m),1.55-1.65(2H,m),1.99-2.00(2H,m),2.17-2.20(2H,m),3.56-3.61(1H,m),4.65-4.70(2H,m),5.00(2H,t,J=8.0Hz),5.10-5.15(1H,m),5.40-5.45(1H,m),6.77(1H,d,J=8.0Hz),7.09(1H,d,J=8.0Hz),7.17(1H,d,J=8.0Hz),7.57(1H,q,J=4.0Hz),7.80(1H,d,J=8.0Hz),8.14(1H,s),8.32(1H,s),8.51(1H,dt,J=8.0,4.0Hz),8.60(1H,d,J=4.0Hz),8.71(1H,d,J=8.0Hz),8.75(1H,dd,J=8.0,4.0Hz),9.35(1H,d,J=4.0Hz).
MS(ESI)[M+H]+:530.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.29-1.37(2H,m),1.44-1.55(2H,m),1.96-2.10(4H,m),2.4(3H,s),3.50-3.57(2H,m),3.63(2H,t,J=8.0Hz),3.86(2H,t,J=8.0Hz),4.95(1H,bs),5.11(1H,t,J=8.0Hz),5.65(1H,s),6.81(1H,d,J=8.0Hz),7.05(1H,d,J=8.0Hz),7.10-7.20(2H,d,J=8.0Hz),8.07(1H,s),8.14(1H,s),8.58(1H,s).
MS(ESI)[M+H]+:481.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.34-1.45(2H,m),1.51-1.59(2H,m),1.96-2.10(4H,m),2.87(3H,s),3.50-3.57(2H,m),3.06(2H,bs),3.86(2H,t,J=8.0Hz),4.82(1H,bs),6.06(1H,s),7.10-7.20(2H,d,J=8.0Hz),8.21(1H,s),8.30(1H,s),8.41(1H,s),8.55(1H,s).
MS(ESI)[M+H]+:509.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.30-1.40(2H,m),1.45-1.55(2H,m),1.96-2.10(4H,m),3.54-3.52(4H,m),3.66(8H,s),4.62-4.65(2H,m),4.96(3H,t,J=8.0Hz),5.31-5.40(1H,m),6.06(1H,d,J=8.0Hz),6.66(1H,d,J=8.0Hz),6.78(1H,dd,J=8.0,4.0Hz),7.05(1H,d,J=8.0Hz),8.06(1H,s),8.10(1H,d,J=8.0Hz),8.24(1H,d,J=4.0Hz).
MS(ESI)[M+H]+:554.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.39-1.51(2H,m),1.58-1.67(2H,m),1.99-2.02(2H,m),2.17-2.20(2H,m),3.53-3.62(1H,m),3.77(3H,s),4.59(2H,d,J=8.0Hz),5.25-5.31(1H,m),5.37(1H,t,J=8.0Hz),6.90(1H,d,J=8.0Hz),7.07(1H,d,J=8.0Hz),7.30(1H,d,J=4.0Hz),7.57(1H,q,J=4.0Hz),8.28(1H,s),8.53(1H,d,J=4.0Hz),8.60-8.67(2H,m),8.73(1H,dd,J=8.0,4.0Hz),9.50(1H,d,J=4.0Hz).
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.30-1.53(4H,m),1.42(3H,t,J=8.0Hz),1.95-2.08(4H,m),3.50-3.53(1H,m),3.66(s,8H),4.18(2H,q,J=8.0Hz),4.94-4.99(1H,m),6.06(1H,d,J=4.0Hz),7.11(2H,d,J=4.0Hz),7.20(1H,dd,J=8.0,4.0Hz),7.96(1H,s),8.10(1H,d,J=8.0Hz),8.53(1H,d,J=4.0Hz).
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.40-1.66(4H,m),1.99-2.05(2H,m),2.19-2.21(2H,m),3.58-3.62(1H,m),4.65-4.70(2H,m),5.00(2H,t,J=8.0Hz),5.26-5.32(1H,m),5.40-5.46(1H,m),6.76(1H,d,J=8.0Hz),6.97(1H,d,J=8.0Hz),7.11(1H,d,J=8.0Hz),7.17(1H,dd,J=8.0,4.0Hz),8.15(1H,s),8.24(2H,dd,J=8.0,4.0Hz),8.59(1H,d,J=4.0Hz),8.69(1H,d,J=8.0Hz),8.78(2H,dd,J=8.0,4.0Hz).
1H-NMR(400MHz,CD3OD)δ(ppm):1.37-1.50(2H,m),1.50-1.60(2H,m),2.00-2.20(4H,m),3.40(4H,t,J=8.0Hz),3.60-3.65(1H,m),3.78(1H,t,J=8.0Hz),3.90(3H,s),4.40-4.50(1H,m),6.27(1H,d,J=4.0Hz),6.39(1H,dd,J=8.0,4.0Hz),6.80(1H,dd,J=8.0,4.0Hz),6.96(1H,d,J=8.0Hz),7.91(1H,d,J=4.0Hz),8.10(1H,s).
1H-NMR(400MHz,CD3OD)δ(ppm):1.40-1.50(2H,m),1.60-1.70(2H,m),2.00-2.20(4H,m),3.60-3.65(1H,m),3.90(3H,s),4.40-4.60(1H,m),6.80(1H,dd,J=9.0,4.0Hz),6.91-7.00(3H,m),8.09(1H,dd,J=8.0,4.0Hz),8.30(1H,d,J=4.0Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.25-1.41(2H,m),1.62-1.65(2H,m),1.92(1H,brs),2.16-2.19(4H,m),3.74-3.76(9H,m),3.80(3H,s),4.61(1H,d,J=8.3Hz),4.73(2H,d,J=4.9Hz),4.96(1H,brs),5.98(1H,d,J=5.6Hz),6.74(1H,s),6.93(1H,d,J=2.4Hz),8.01(1H,d,J=2.2Hz),8.06(1H,d,J=5.6Hz).
MS(ESI)[M+H]+:542.
1H-NMR(400MHz,CD3OD)δ(ppm):1.25-1.41(2H,m),1.62-1.65(2H,m),1.92(1H,s),1.20-1.30(2H,m),1.40-1.50(2H,m),2.00-2.20(4H,m),3.40-3.50(1H,m),3.55-3.65(1H,m),4.61(2H,s),4.64(2H,s),7.23(1H,s),7.43(2H,d,J=8.0Hz),7.47(1H,s),7.73(1H,s),8.47(1H,d,J=8.0,4.0Hz).
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.36-1.51(4H,m),1.91-2.06(4H,m),2.36(s,4H),3.48(s,2H),3.58(4H,t,J=4.0Hz),3.66(s,8H),6.07(1H,d,J=4.0Hz),6.20(1H,d,J=8.0Hz),7.14(1H,s),7.44(1H,s),7.87(1H,s),8.09(1H,d,J=8.0Hz),8.80(s,1H).
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.31-1.53(4H,m),1.92-2.08(4H,m),3.65(s,8H),4.56(2H,d,J=8.0Hz),5.31(1H,t,J=8.0Hz),6.05(1H,d,J=4.0Hz),6.16(1H,d,J=4.0Hz),7.48(1H,d,J=8.0Hz),7.57(1H,d,J=8.0Hz),7.91(1H,s),8.01(1H,d,J=8.0Hz),8.67(1H,s).
1H-NMR(400MHz,CDCl3)δ(ppm):1.23-1.38(2H,m),1.65-1.70(2H,m),2.17(4H,t,J=14.8Hz),2.94(3H,d,J=5.1Hz),3.49(1H,d,J=3.7Hz),3.73-3.74(1H,m),3.87(3H,s),4.49(1H,d,J=7.6Hz),4.89(1H,brs),5.98(1H,d,J=5.6Hz),6.78-6.80(2H,m),6.82(1H,s),7.96(1H,s),8.15(1H,s).
MS(ESI)[M+H]+:456.
1H-NMR(400MHz,CDCl3)δ(ppm):1.28-1.35(2H,m),1.67-1.72(2H,m),2.15-2.18(4H,m),3.60-3.61(4H,m),3.75-3.76(5H,m),4.62(1H,d,J=7.6Hz),4.88-4.90(1H,m),6.14(1H,d,J=6.1Hz),6.77-6.80(2H,m),6.88(1H,s),8.02(1H,d,J=6.1Hz),8.14(1H,d,J=0.7Hz).
MS(ESI)[M+H]+:512.
1H-NMR(400MHz,CD3OD)δ(ppm):1.25-1.38(2H,m),1.40-1.53(2H,m),2.00-2.15(4H,m),3.41-3.49(1H,m),3.57-3.64(1H,m),4.61(2H,s),4.75-4.82(2H,m),5.03-5.07(2H,t,J=8.0Hz),5.37-5.42(1H,m),6.70(1H,d,J=8.0Hz),7.16(1H,dd,J=8.0,4.0Hz),7.42(1H,d,J=8.0Hz),8.46-8.50(3H,m).
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.29-1.41(2H,m),1.51-1.60(2H,m),1.96-2.14(4H,m),2.80-2.83(4H,m),3.50-3.60(1H,m),3.79-3.87(4H,m),4.91-4.99(1H,m),7.11(1H,t,J=8.0Hz),7.23-7.25(1H,m),7.30-7.32(2H,m),7.90(1H,s),8.51(1H,d,J=4.0Hz),8.59(1H,s),8.61(1H,s).
1H-NMR(400MHz,CD3OD)δ(ppm):1.32-1.41(2H,m),1.52-1.62(2H,m),1.97-2.12(4H,m),3.50-3.60(1H,m),4.91-4.99(1H,m),7.11(1H,t,J=8.0Hz),7.24-7.29(2H,m),7.65(1H,d,J=8.0Hz),8.30(1H,s),8.60(2H,d,J=4.0Hz),8.67(1H,d,J=4.0Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.34-1.37(2H,m),1.55-1.61(2H,m),2.13-2.16(4H,m),3.54-3.55(4H,m),3.76-3.77(5H,m),3.87(3H,s),4.47(1H,d,J=7.1Hz),5.02(1H,brs),5.78(1H,s),6.79-6.81(3H,m),8.15(1H,s),8.30(1H,s).
MS(ESI)[M+H]+:512.
1H-NMR(400MHz,CDCl3)δ(ppm):1.36-1.38(2H,m),1.55-1.58(2H,m),2.13-2.17(4H,m),2.87(3H,d,J=5.1Hz),3.76(1H,brs),3.87(3H,s),4.47(1H,s),4.85(1H,brs),5.01(1H,s),5.62(1H,s),6.79-6.81(3H,m),8.15(1H,s),8.21(1H,s).
MS(ESI)[M+H]+:456.
1H-NMR(400MHz,CD3OD)δ(ppm):1.38-1.44(2H,m),1.57-1.63(2H,m),2.09-2.15(4H,m),3.47(2H,t,J=5.9Hz),3.62-3.71(3H,m),3.80(3H,s),4.70(2H,s),5.03-5.08(1H,m),5.99(1H,d,J=5.9Hz),7.36(1H,d,J=1.5Hz),7.91(1H,d,J=5.6Hz),8.41(1H,d,J=2.2Hz).
MS(ESI)[M+H]+:500.
1H-NMR(400MHz,CDCl3)δ(ppm):1.30-1.35(2H,m),1.59-1.62(2H,m),2.13-2.15(4H,m),3.55-3.57(2H,m),3.74-3.76(1H,m),3.82-3.83(2H,m),3.87(3H,s),4.52-4.54(1H,m),4.91-4.94(1H,m),5.34(1H,s),6.01(1H,d,J=5.9Hz),6.78-6.82(2H,m),6.83(1H,s),7.97(1H,d,J=5.9Hz),8.14(1H,s).
MS(ESI)[M+H]+:486.
1H-NMR(400MHz,CDCl3)δ(ppm):1.32-1.55(4H,m),2.12(4H,d,J=8.5Hz),3.57(2H,dd,J=10.0,5.4Hz),3.71-3.75(1H,m),3.84(2H,t,J=4.8Hz),4.78(2H,dd,J=7.6,4.9Hz),4.90-4.94(1H,m),5.03(2H,t,J=6.7Hz),5.28(1H,dd,J=10.6,4.8Hz),5.45-5.49(1H,m),6.01(1H,d,J=5.9Hz),6.43(1H,d,J=8.5Hz),7.15(2H,d,J=8.5Hz),7.97(1H,d,J=5.9Hz),8.58(1H,s).
MS(ESI)[M+H]+:512.
1H-NMR(400MHz,CD3OD)δ(ppm):1.41-1.44(2H,m),1.58-1.60(2H,m),2.10-2.17(4H,m),2.88(3H,s),3.61-3.70(1H,m),4.74-4.77(2H,m),5.02-5.06(3H,m),5.38-5.42(1H,m),5.97(1H,d,J=6.1Hz),6.68(1H,d,J=8.0Hz),7.17(1H,d,J=9.8Hz),7.91(1H,d,J=5.4Hz),8.49(1H,s).
MS(ESI)[M+H]+:482.
1H-NMR(400MHz,CD3OD)δ(ppm):1.41(2H,t,J=11.6Hz),1.59(2H,t,J=10.9Hz),2.09-2.16(4H,m),2.88(3H,s),3.61-3.65(1H,m),3.80(3H,s),4.70(2H,s),5.07(1H,d,J=4.4Hz),5.97(1H,d,J=5.9Hz),7.36(1H,s),7.91(1H,d,J=5.9Hz),8.41(1H,d,J=1.7Hz).
1H-NMR(400MHz,CD3OD)δ(ppm):1.29-1.38(2H,m),1.52-1.69(2H,m),2.01-2.20(4H,m),3.60-3.68(1H,m),4.77-4.80(2H,m),5.01-5.08(2H,m),5.10-5.21(1H,m),5.38-5.43(1H,m),6.67-6.73(1H,m),6.84(1H,d,J=8.0Hz),7.16-7.25(1H,m),8.41(1H,d,J=8.0Hz),8.49(1H,d,J=4.0Hz),8.70(1H,s).
1H-NMR(400MHz,CDCl3)δ(ppm):1.20-1.28(2H,m),1.48-1.52(2H,m),2.00-2.02(1H,m),2.10-2.12(4H,m),3.35(1H,brs),3.69(1H,brs),3.78(3H,s),4.57(2H,s),4.60(1H,d,J=8.0Hz),4.72(2H,d,J=6.1Hz),6.74(1H,s),6.92(1H,d,J=1.7Hz),7.28-7.30(2H,m),7.69(1H,d,J=7.3Hz),8.03(1H,d,J=2.4Hz),8.54(1H,dd,J=4.9,1.7Hz),8.56(1H,d,J=1.5Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.19-1.22(2H,m),1.47-1.50(2H,m),2.11(4H,s),3.36-3.38(1H,m),3.68-3.71(1H,m),3.86(3H,s),4.44(1H,brs),4.57(2H,s),6.78-6.80(3H,m),7.26-7.31(1H,m),7.70(1H,d,J=7.8Hz),8.14(1H,s),8.54(1H,dd,J=4.9,1.5Hz),8.57(1H,d,J=2.4Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.21-1.24(2H,m),1.47-1.50(2H,m),2.11-2.13(4H,m),3.36(1H,brs),3.71(1H,brs),3.91(3H,s),4.45(1H,d,J=7.3Hz),4.57(2H,s),6.81(1H,s),6.88(1H,d,J=8.8Hz),7.22-7.24(1H,m),7.27-7.31(1H,m),7.70(1H,d,J=8.0Hz),8.49(1H,s),8.54(1H,d,J=4.6Hz),8.58(1H,s).
1H-NMR(400MHz,CD3OD)δ(ppm):1.38-1.43(2H,m),1.56-1.62(2H,m),2.08-2.14(4H,m),2.84(3H,s),3.62-3.65(1H,m),3.75(3H,s),4.66(2H,s),4.86-4.89(1H,m),5.71(1H,s),6.95(1H,s),8.05(1H,s),8.08(1H,s).
1H-NMR(400MHz,CD3OD)δ(ppm):1.38-1.44(3H,m),1.57-1.62(2H,m),2.08-2.14(4H,m),2.84(3H,s),3.63-3.65(1H,m),3.80(3H,s),4.70(2H,s),4.84-4.86(1H,m),5.71(1H,s),7.36(1H,s),8.08(1H,s),8.41(1H,d,J=1.7Hz).
MS(ESI)[M+H]+:470.
1H-NMR(400MHz,CDCl3)δ(ppm):1.11-1.16(4H,m),1.55-1.57(1H,m),1.87-1.90(2H,m),2.08-2.10(2H,m),3.32(2H,d,J=6.3Hz),3.63(1H,brs),3.86(3H,s),4.44(1H,d,J=7.6Hz),4.51(2H,s),6.77-6.79(3H,m),7.27-7.30(1H,m),7.67(1H,d,J=8.0Hz),8.14(1H,s),8.54(1H,dd,J=4.8,1.6Hz),8.57(1H,d,J=1.5Hz).
MS(ESI)[M+H]+:454.
1H-NMR(400MHz,CDCl3)δ(ppm):1.10-1.26(4H,m),1.55-1.57(1H,m),1.88-1.90(2H,m),2.05-2.10(2H,m),3.32(2H,d,J=6.3Hz),3.62(1H,brs),3.91(3H,s),4.44(1H,d,J=7.6Hz),4.51(2H,s),6.79(1H,s),6.88(1H,d,J=8.5Hz),7.29-7.30(2H,m),7.67(1H,d,J=7.8Hz),8.49(1H,d,J=2.0Hz),8.54(1H,dd,J=4.9,1.7Hz),8.57(1H,d,J=2.0Hz).
1H-NMR(400MHz,CDCl3)δ(ppm):1.15-1.17(2H,m),1.55-1.57(1H,m),1.90-1.93(2H,m),2.10-2.12(2H,m),3.33(2H,d,J=6.3Hz),3.65(1H,brs),3.87(3H,s),4.44(1H,d,J=7.3Hz),4.51(2H,s),6.78-6.80(3H,m),7.25-7.26(2H,m),8.15(1H,s),8.57(2H,d,J=5.9Hz).
MS(ESI)[M+H]+:454.
1H-NMR(400MHz,CDCl3)δ(ppm):1.10-1.23(4H,m),1.55-1.57(1H,m),1.89-1.92(2H,m),2.10-2.13(2H,m),3.33(2H,d,J=6.3Hz),3.65(1H,brs),3.91(3H,s),4.49-4.51(3H,m),6.81(1H,s),6.88(1H,d,J=8.5Hz),7.22-7.24(2H,m),8.50(1H,d,J=2.0Hz),8.57(2H,t,J=2.9Hz).
MS(ESI)[M+H]+:454.
1H-NMR(400MHz,CDCl3)δ(ppm):1.19-1.28(2H,m),1.46-1.52(2H,m),2.11-2.14(4H,m),3.34-3.37(1H,m),3.69-3.71(1H,m),4.57(2H,s),4.73-4.78(3H,m),5.01(2H,t,J=6.7Hz),5.25-5.28(1H,m),6.42(1H,d,J=8.5Hz),6.89-6.91(1H,m),7.15-7.16(1H,m),7.29-7.31(1H,m),7.69-7.71(1H,m),8.53-8.58(3H,m).
1H-NMR(400MHz,CD3OD)δ(ppm):1.24-1.30(4H,m),1.81-1.85(1H,m),1.93-1.98(2H,m),2.07-2.10(2H,m),3.52-3.55(1H,m),3.90(3H,s),3.96(2H,d,J=6.1Hz),6.78-6.81(1H,m),6.96(1H,d,J=9.0Hz),7.82(1H,t,J=2.3Hz),8.09-8.09(1H,m),8.37(1H,d,J=2.9Hz),8.60(1H,d,J=1.7Hz).
1H-NMR(400MHz,CD3OD)δ(ppm):1.20-1.32(4H,m),1.79-1.89(1H,m),2.00-2.04(4H,m),3.53(1H,brs),3.86(2H,d,J=6.3Hz),3.90(2H,brs),6.80(1H,dd,J=8.8,2.0Hz),6.96(1H,d,J=9.0Hz),7.08-7.10(1H,m),7.35(1H,t,J=8.2Hz),7.41-7.43(2H,m),8.09(1H,d,J=2.9Hz).
MS(ESI)[M+H]+:482.
1H-NMR(400MHz,DMSO-d6)δ(ppm):1.41-1.51(2H,m),1.57-1.67(2H,m),1.99-2.02(2H,m),2.17-2.20(2H,m),3.53-3.62(1H,m),3.69(3H,s),4.57(2H,d,J=8.0Hz),5.24-5.38(1H,m),5.33(1H,t,J=8.0Hz),6.90-6.96(2H,m),7.06(1H,d,J=8.0Hz),7.57(1H,q,J=4.0Hz),8.16(1H,d,J=4.0Hz),8.24(1H,s),8.60-8.67(2H,m),8.73(1H,dd,J=8.0,4.0Hz),9.50(1H,d,J=4.0Hz).
1H-NMR(400MHz,CD3OD)δ(ppm):1.38-1.61(4H,m),2.08-2.16(4H,m),2.88(3H,s),3.63(1H,brs),3.75(3H,s),4.66(2H,s),5.07(1H,brs),5.97(1H,d,J=5.9Hz),6.94(1H,s),7.91(1H,d,J=5.9Hz),8.04(1H,d,J=2.9Hz).
実施例1~80の化合物のDDR1阻害活性をHTRF(登録商標)KinEASE-TK kit(Cisbioバイオアッセイズ社)を使用し、評価した。
阻害率(%)=([被験物質非添加のRatio]-[被験物質のRatio])/([被験物質非添加のRatio]-[DDR1細胞内ドメイン非添加かつ被験物質非添加のRatio])×100
Claims (5)
- 一般式(I)で示される尿素誘導体又はその薬理学的に許容される塩。
R2は、それぞれ独立して、水素原子、又は、一つの水酸基若しくは一つの環構成原子数4~6の飽和ヘテロシクリル基で置換されていてもよいメチル基を表し、
R3は、水素原子、ハロゲン原子、炭素数1~3のアルキル基、オキソ基を有していてもよい環構成原子数4~6の飽和ヘテロシクリル基又はR5O-を表し、
R4は、一つのR6で置換されていてもよい、フェニル基、ピリジル基、ピリダジニル基又はピリミジニル基を表し、
m及びnは、それぞれ独立して、0又は1を表し、
R5は、炭素数1~3のアルキル基、又は、環構成原子数4~6の飽和ヘテロシクリル基を表し(ただし、R5の環構成原子が窒素原子を含む場合は、前記窒素原子がアセチル基で置換されていてもよい。)、
R6は、カルバモイル基、フェニル基、環構成原子数5若しくは6のヘテロアリール基、環構成原子数4~6の飽和ヘテロシクリル基又は(R7)R8N-を表し、
R7及びR8は、それぞれ独立して、水素原子、又は、水酸基で置換されていてもよい炭素数1~3のアルキル基を表す(ただし、m及びnが0であり、かつ、R4がカルバモイル基で置換されている、フェニル基又はピリジル基である場合を除く。)。] - R2は、それぞれ独立して、水素原子又はヒドロキシメチル基であり、
R3は、水素原子、モルホリニル基、3-オキソピペラジニル基又はR5O-であり、
R4は、一つのR6で置換されていてもよい、ピリジル基又はピリミジニル基であり、
R5は、炭素数1~3のアルキル基、3-オキセタニル基、又は、窒素原子がアセチル基で置換されていてもよい、3-アゼチジニル基、3-ピロリジニル基若しくは4-ピペリジニル基であり、
R6は、カルバモイル基、ピリジル基、モルホリニル基又は(R7)R8N-である、請求項1記載の尿素誘導体又はその薬理学的に許容される塩。 - 請求項1~4のいずれか一項記載の尿素誘導体又はその薬理学的に許容される塩を有効成分として含有する、ディスコイジンドメイン受容体1の阻害剤。
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2991697A CA2991697A1 (en) | 2015-08-31 | 2016-08-31 | Urea derivative and use therefor |
KR1020177033605A KR20180043200A (ko) | 2015-08-31 | 2016-08-31 | 요소 유도체 및 그 용도 |
ES16841903T ES2764731T3 (es) | 2015-08-31 | 2016-08-31 | Derivado de urea y utilización del mismo |
RU2018109256A RU2018109256A (ru) | 2015-08-31 | 2016-08-31 | Производное мочевины и его применение |
BR112018002127-0A BR112018002127A2 (ja) | 2015-08-31 | 2016-08-31 | A urea derivative and its use |
EP16841903.4A EP3345893B1 (en) | 2015-08-31 | 2016-08-31 | Urea derivative and use therefor |
AU2016317531A AU2016317531A1 (en) | 2015-08-31 | 2016-08-31 | Urea derivative and use therefor |
JP2016556023A JPWO2017038873A1 (ja) | 2015-08-31 | 2016-08-31 | 尿素誘導体及びその用途 |
US15/753,567 US10280145B2 (en) | 2015-08-31 | 2016-08-31 | Urea derivative and use therefor |
MX2018002018A MX2018002018A (es) | 2015-08-31 | 2016-08-31 | Derivado de urea y uso del mismo. |
CN201680049418.9A CN107922319A (zh) | 2015-08-31 | 2016-08-31 | 尿素衍生物和其用途 |
HK18107600.7A HK1248209A1 (zh) | 2015-08-31 | 2018-06-12 | 尿素衍生物和其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-170015 | 2015-08-31 | ||
JP2015170015 | 2015-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017038873A1 true WO2017038873A1 (ja) | 2017-03-09 |
Family
ID=58188928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/075500 WO2017038873A1 (ja) | 2015-08-31 | 2016-08-31 | 尿素誘導体及びその用途 |
Country Status (14)
Country | Link |
---|---|
US (1) | US10280145B2 (ja) |
EP (1) | EP3345893B1 (ja) |
JP (1) | JPWO2017038873A1 (ja) |
KR (1) | KR20180043200A (ja) |
CN (1) | CN107922319A (ja) |
AU (1) | AU2016317531A1 (ja) |
BR (1) | BR112018002127A2 (ja) |
CA (1) | CA2991697A1 (ja) |
ES (1) | ES2764731T3 (ja) |
HK (1) | HK1248209A1 (ja) |
MX (1) | MX2018002018A (ja) |
RU (1) | RU2018109256A (ja) |
TW (1) | TW201718475A (ja) |
WO (1) | WO2017038873A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108276388A (zh) * | 2017-03-10 | 2018-07-13 | 成都医学院 | 1h-吲哚类衍生物及其用途 |
CN108368060A (zh) * | 2017-12-21 | 2018-08-03 | 中国科学院合肥物质科学研究院 | 一类新型的嘧啶类衍生物激酶抑制剂 |
WO2019119486A1 (zh) * | 2017-12-21 | 2019-06-27 | 中国科学院合肥物质科学研究院 | 一类嘧啶类衍生物激酶抑制剂 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022547777A (ja) * | 2019-09-06 | 2022-11-16 | 小野薬品工業株式会社 | ヒダントイン誘導体 |
CN111196783B (zh) * | 2020-01-19 | 2022-09-27 | 郑州大学 | 含酰基脲结构的2,4,6-取代嘧啶类衍生物及其制备方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102319242A (zh) * | 2011-10-13 | 2012-01-18 | 济南海乐医药技术开发有限公司 | 吲唑双芳基脲化合物作为蛋白激酶抑制剂的应用 |
WO2014032755A2 (en) * | 2012-08-29 | 2014-03-06 | Merck Patent Gmbh | Ddr2 inhibitors for the treatment of osteoarthritis |
WO2015038778A1 (en) * | 2013-09-11 | 2015-03-19 | The Brigham And Women's Hospital, Inc. | SUBSTITUTED UREA EIF2α KINASE ACTIVATORS |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200740820A (en) * | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
WO2011040509A1 (ja) | 2009-09-30 | 2011-04-07 | 東レ株式会社 | 2,3-ジヒドロ-1h-インデン-2-イルウレア誘導体及びその医薬用途 |
CN101885722B (zh) | 2010-07-01 | 2013-07-24 | 中国科学院广州生物医药与健康研究院 | 杂环炔苯类化合物及其药用组合物和应用 |
WO2012112570A1 (en) * | 2011-02-14 | 2012-08-23 | The Regents Of The University Of California | SORAFENIB DERIVATIVES AS sEH INHIBITORS |
WO2013155047A2 (en) * | 2012-04-10 | 2013-10-17 | Trustees Of Dartmouth College | Compounds and methods for inhibiting cif virulence factor |
US9567304B2 (en) | 2012-04-24 | 2017-02-14 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinedione derivative |
BR112014026266A2 (pt) | 2012-04-24 | 2017-06-27 | Chugai Pharmaceutical Co Ltd | derivado de quinazolidinadiona |
WO2014007998A1 (en) * | 2012-07-06 | 2014-01-09 | The Regents Of The University Of California | SORAFENIB DERIVATIVES AS p21 INHIBITORS |
-
2016
- 2016-08-31 JP JP2016556023A patent/JPWO2017038873A1/ja not_active Withdrawn
- 2016-08-31 US US15/753,567 patent/US10280145B2/en active Active
- 2016-08-31 EP EP16841903.4A patent/EP3345893B1/en active Active
- 2016-08-31 AU AU2016317531A patent/AU2016317531A1/en not_active Abandoned
- 2016-08-31 KR KR1020177033605A patent/KR20180043200A/ko unknown
- 2016-08-31 CN CN201680049418.9A patent/CN107922319A/zh not_active Withdrawn
- 2016-08-31 WO PCT/JP2016/075500 patent/WO2017038873A1/ja active Application Filing
- 2016-08-31 TW TW105127962A patent/TW201718475A/zh unknown
- 2016-08-31 MX MX2018002018A patent/MX2018002018A/es unknown
- 2016-08-31 CA CA2991697A patent/CA2991697A1/en not_active Abandoned
- 2016-08-31 RU RU2018109256A patent/RU2018109256A/ru not_active Application Discontinuation
- 2016-08-31 BR BR112018002127-0A patent/BR112018002127A2/ja not_active Application Discontinuation
- 2016-08-31 ES ES16841903T patent/ES2764731T3/es active Active
-
2018
- 2018-06-12 HK HK18107600.7A patent/HK1248209A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102319242A (zh) * | 2011-10-13 | 2012-01-18 | 济南海乐医药技术开发有限公司 | 吲唑双芳基脲化合物作为蛋白激酶抑制剂的应用 |
WO2014032755A2 (en) * | 2012-08-29 | 2014-03-06 | Merck Patent Gmbh | Ddr2 inhibitors for the treatment of osteoarthritis |
WO2015038778A1 (en) * | 2013-09-11 | 2015-03-19 | The Brigham And Women's Hospital, Inc. | SUBSTITUTED UREA EIF2α KINASE ACTIVATORS |
Non-Patent Citations (1)
Title |
---|
TING CHEN ET AL.: "Explorations of Substituted Urea Functionality for the Discovery of New Activators of the Heme-Regulated Inhibitor Kinase", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 23, 2013, pages 9457 - 9470, XP055366582 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108276388A (zh) * | 2017-03-10 | 2018-07-13 | 成都医学院 | 1h-吲哚类衍生物及其用途 |
CN108368060A (zh) * | 2017-12-21 | 2018-08-03 | 中国科学院合肥物质科学研究院 | 一类新型的嘧啶类衍生物激酶抑制剂 |
WO2019119486A1 (zh) * | 2017-12-21 | 2019-06-27 | 中国科学院合肥物质科学研究院 | 一类嘧啶类衍生物激酶抑制剂 |
JP2021506935A (ja) * | 2017-12-21 | 2021-02-22 | ヘフェイ インスティテューツ オブ フィジカル サイエンス, チャイニーズ アカデミー オブ サイエンシーズ | ピリミジン誘導体系キナーゼ阻害剤類 |
JP7021356B2 (ja) | 2017-12-21 | 2022-02-16 | ヘフェイ インスティテューツ オブ フィジカル サイエンス, チャイニーズ アカデミー オブ サイエンシーズ | ピリミジン誘導体系キナーゼ阻害剤類 |
US11602534B2 (en) | 2017-12-21 | 2023-03-14 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Pyrimidine derivative kinase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
AU2016317531A1 (en) | 2018-02-22 |
US20180237398A1 (en) | 2018-08-23 |
US10280145B2 (en) | 2019-05-07 |
BR112018002127A2 (ja) | 2018-09-11 |
JPWO2017038873A1 (ja) | 2018-06-14 |
CA2991697A1 (en) | 2017-03-09 |
RU2018109256A (ru) | 2019-10-07 |
HK1248209A1 (zh) | 2018-10-12 |
KR20180043200A (ko) | 2018-04-27 |
EP3345893A1 (en) | 2018-07-11 |
TW201718475A (zh) | 2017-06-01 |
CN107922319A (zh) | 2018-04-17 |
ES2764731T3 (es) | 2020-06-04 |
EP3345893A4 (en) | 2019-01-16 |
EP3345893B1 (en) | 2019-10-30 |
MX2018002018A (es) | 2018-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102644798B1 (ko) | Erk1 및 erk2의 헤테로사이클릭 억제제 및 암 치료에서 이의 용도 | |
WO2017038873A1 (ja) | 尿素誘導体及びその用途 | |
TWI585088B (zh) | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 | |
JP6923543B2 (ja) | Nr2b選択的nmda調節因子としての置換1,2,3−トリアゾール | |
JP4782239B2 (ja) | 異常細胞増殖治療のためのスルホニルアミド誘導体 | |
KR102327917B1 (ko) | 신규한 4-아미노피라졸로[3,4-d]피리미디닐아자바이사이클로 유도체 및 이를 포함하는 약학 조성물 | |
US20230103791A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
US10336697B2 (en) | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | |
CA2683624A1 (en) | Pharmaceutical compounds | |
CA2683622A1 (en) | 2-morpholin-4-yl-pyrimidines as pi3k inhibitors | |
WO2015025197A1 (en) | Substituted pyrimidine compounds, compositions and medicinal applications thereof | |
EP2933248A1 (en) | Novel renin inhibitor | |
CN111417628A (zh) | 作为ehmt2抑制剂的胺取代的杂环化合物、其盐及其合成方法 | |
KR20230116795A (ko) | 피리미딘 화합물, 조성물, 및 이들의 의약적 응용 | |
EP4114829A1 (en) | Monoacylglycerol lipase inhibitors | |
US10519106B2 (en) | Urea derivative and use therefor | |
WO2019141096A1 (zh) | 取代脲类化合物及其制备方法和用途 | |
WO2022067063A1 (en) | Mutant selective egfr inhibitors and methods of use thereof | |
CN116685583A (zh) | 嘧啶化合物、组合物及其医药应用 | |
WO2021210650A1 (ja) | アリールまたはヘテロアリール誘導体 | |
TW202115023A (zh) | 新型細胞凋亡訊號調節激酶1抑制劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2016556023 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16841903 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20177033605 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2991697 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2018/002018 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15753567 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016317531 Country of ref document: AU Date of ref document: 20160831 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018109256 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018002127 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016841903 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112018002127 Country of ref document: BR Kind code of ref document: A2 Effective date: 20180131 |